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Summary
Multiple sclerosis (MS) is the most common chronic inflammatory disease of the central
nervous system and often leads to severe disability. According to data from the animal model
for MS, experimental autoimmune encephalomyelitis (EAE), MS has been thought to be
mostly T cell mediated. However, immunoglobulin deposits at MS lesion sites and the
presence of oligoclonal immunoglobulins in the cerebrospinal fluid (CSF) of more than 95%
of all MS patients, detectable by isoelectric focusing electrophoresis as so-called oligoclonal
bands (OCB), support an involvement of the humoral immune response in the pathogenesis
of MS.
Assuming that OCB are the product of CSF plasma cells, we sought to resolve the
immunopathological relevance of these clonally expanded immunoglobulins by means of
single cell PCR of CSF plasma cell-immunoglobulin genes and recombinant resurrection of
original antibody heavy (H) and light (L) chain gene pairings. We obtained nine antibodies
from clonally expanded CSF plasma cells (cePC) of four different MS patients (MS-mAb). By
staining post-mortem MS brain tissue, we showed that eight MS-mAb specifically bind to
myelin, while sparing the axon. Myelin reactivity was most pronounced at the rim of MS
lesions, whereas it was very weak or undetectable in the lesion itself and in normal
appearing white matter. This indicates that the cognate antigens are either induced,
upregulated or more accessible at the rim of inflammatory lesions. One of the MS-mAb
stained filamentous structures in astrocytes and in non-brain tissue, whereas the myelin
reactive MS-mAb showed no reactivity towards non-brain tissue. By competition
experiments, we were able to demonstrate that a diverse repertoire of myelin epitope
recognition was present among the myelin-reactive MS-mAb. The identity of the cognate
antigens of the MS-mAb remain to be determined by ongoing experiments.
To be able to investigate the effect of humoral immune mechanisms independently from the
contribution of the cellular immune effector arm, we established an experimental system
using organotypic cerebellar slice cultures (OSC) from transgenic mice expressing green
fluorescent protein (GFP) in myelin (PLP-GFP). This system allowed us to live visualize
demyelination and remyelination and promised to be a suitable readout for the evaluation of
the pathophysiological relevance of the MS-mAb described above.
Applying a myelin specific antibody of known demyelinating capability in the presence of
complement, we demonstrated by confocal live imaging that demyelination started at the thin
extension fibers of the cerebellum, before degradation was visible at the thicker central
branches. Demyelination was accompanied by oligodendrocyte loss, while axonal
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morphology remained preserved. The MS-mAb were tested in the same system. However,
none of the nine MS-mAb induced any morphological changes in OSC, suggesting that the
MS-mAb either specifically recognize human structures or antigens only expressed or
accessible to antibody binding during an active inflammatory response. Overall, our findings
indicate that a single event of antibody/complement-mediated demyelination alone is not
sufficient for the axonal damage seen in MS lesions, but may render naked axons
susceptible to damage elicited by other mechanisms. However, we cannot exclude that
repeated and/or prolonged demyelination may lead to secondary axonal damage.
After removal of the detrimental antibody and complement, spontaneous remyelination was
observed in OSC, as visualized by confocal live imaging. Remyelination was guided along
surviving axons, further supporting their integrity. Additionally, we were able to show that
oligodendrocyte precursor cells are present in OSC and proliferate following the
demyelinating attack. It is therefore reasonable to assume that oligodendrocyte precursor
cells are responsible for the remyelination.
We provide an experimental system, which allows for the visualization of de- and
remyelination in an ex vivo situation. Moreover, OSC may be a useful tool for the evaluation
of therapeutic strategies to prevent demyelination and enhance remyelination and repair in
MS and other demyelinating diseases.
Zusammenfassung
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Zusammenfassung
Multiple Sklerose (MS) ist die häufigste chronisch-entzündliche Erkrankung des zentralen
Nervensystems (ZNS), welche oft zu schweren Behinderungen führt. Aufgrund von
tierexperimentellen Daten wurde die MS als überwiegend T Zell vermittelte Erkrankung
betrachtet. Auf der anderen Seite deuten Ablagerungen von Antikörpern in ZNS-Läsionen
von MS Patienten und oligoklonale Immunoglobuline (Ig), welche als typische oligoklonale
Banden (OKB) im Liquor cerebrospinalis von mehr als 95% aller MS-Patienten nachweisbar
sind, darauf hin, dass auch B Zellen und Antikörper in den Krankheitsprozess involviert sind.
Unter der Annahme, dass OKB von Plasmazellen im Liquor cerebrospinalis von MS
Patienten produziert werden, etablierten wir die Herstellung rekombinanter humaner
Antikörper aus einzelnen, klonal expandierten Liquor-Plasmazellen, um deren Rolle im
Krankheitsprozess der MS näher charakterisieren zu können. Zu diesem Zweck
amplifizierten wir zunächst die Ig Schwer- und Leichtkettengene einzelner, FACS-sortierter
Liquor-Plasmazellen. Durch Analyse der Nukleotidsequenzen der amplifizierten Ig-
Schwerkettengene identifizerten wir expandierte Plasmazellklone und klonierten deren Ig
Schwer- und Leichtkettengene in Expressionsvektoren, um sie in Form rekombinanter
Antikörper in eukaryotischen Zellen zu rekonstituieren. Auf diese Weise haben wir neun
monoklonale Antikörper (MS-mAk) aus klonal expandierten Liquor-Plasmazellen von vier
verschiedenen MS Patienten produziert. Acht der MS-mAk zeigten eine spezifische Bindung
an Myelin und zwar mit eindeutiger Präferenz für den Randbereich demyelinisierender
Läsionen in postmortalem Gehirngewebe von MS Patienten, während die Läsion selbst und
das die Läsion umgebende Gewebe nicht oder wenig von den MS-mAk gefärbt wurde. Diese
Daten legen die Vermutung nahe, dass die Zielantigene der MS-mAk im Randbereich von
MS-Läsionen in höherer Konzentration vorhanden oder besser zugänglich sind. Einer der
MS-mAk zeigte im Unterschied dazu Bindung an Filament-ähnliche Strukturen in ZNS-
Astrozyten, aber auch in Zellen anderer Gewebe, während die myelinreaktiven MS-mAk
nicht an die getesteten Kontrollgewebe gebunden haben. In Kompetitionsexperimenten
wurden MS-mAk nur von sich selbst, nicht aber von anderen MS-mAk kompetitiert. Dies
weist darauf hin, dass die MS-mAk unterschiedliche Epitope erkennen. Die Identität der
eigentlichen Zielantigene ist noch nicht entschlüsselt, jedoch Gegenstand aktueller
Untersuchungen.
Um den Effekt humoraler Immunmechanismen unabhängig vom Einfluß zellulärer
Immunkomponeneten untersuchen zu können, etablierten wir ein experimentelles ex vivo
System basierend auf organotypischen ZNS Gewebeschnittkulturen von transgenen
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Mäusen, welche grüne fluoreszierendes Protein (GFP) in Myelin exprimieren. Dieses System
ermöglichte es uns, den Prozess immun-vermittelter Demyelinisierung und Remyelinisierung
durch konfokale Liveaufnahmen zu visualisieren und erschien uns geeignet, um eine
mögliche pathophysioloische Relevanz der MS-mAk zu untersuchen.
Die Zugabe eines myelinspezifischen Antikörpers mit bekannten demyelinisierenden
Eigenschaften zusammen mit Komplement induzierte eine massive Schädigung des Myelins
und den Zelltod von Oligodendrozyten, wobei Axone keinen morphologisch erkennbaren
Schaden erlitten. Im Unterschied dazu induzierte keiner der von uns produzierten MS-mAk
morphologische Änderungen in diesem System, was darauf hindeutet, dass die MS-mAk
entweder spezifisch humane Strukturen oder Antigene erkennen, oder Antigene, welche nur
in einer aktiv-entzündlichen Umgebung exprimiert oder zugängig sind. Insgesamt deuten
unsere Daten darauf hin, dass eine einmalige, durch Antikörper und Komplement vermittelte
Demyelinisierung nicht für die axonalen Schädigungen verantwortlich gemacht werden kann.
Dennoch ist anzunehmen, dass  demyeliniserte Axone empfindlicher gegenüber
Schädigungen durch andere Immunzellen oder veränderte trophische Verhältnisse sind.
Remyelinisierung wird unter anderem mit Remissionen im Krankheitsverlaufs der MS in
Verbindung gebracht. Nach dem Entfernen des myelinschädigenden Antikörpers und
Komplements kam es in unseren Kulturen zu einer spontanen Remyelinisierung der noch
vitalen Axone, sehr wahrscheinlich ausgehend von in den Gewebekulturen residenten
Oligodendrozyten Vorläuferzellen, deren Proliferation nach der demyelinisierenden Attacke
demonstriert werden konnte.
Wir konnten zeigen, dass organotypische ZNS Gewebeschnittkulturen ein geeignetes
System sind, um einerseits Myelin schädigende Mechanismen und trophische Einflüsse
näher zu untersuchen und um andererseits Strategien zur Verhinderung von Schädigungen
oder zur Verbesserung der Remyelinisierung zu entwickeln.
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1 Introduction
As this thesis has a strong focus on the humoral response of the adaptive immune system,
this chapter will mainly provide information on the development and activation of B cells and
describe complement activation. Further, background information on organotypic central
nervous system (CNS) slice cultures, which were applied to study antibody-mediated
demyelination, will be provided.
1.1 Immunobiology
1.1.1 B cell development
B cells derive from hematopoietic stem cells in the bone marrow (Benschop and Cambier,
1999; Goldsby et al., 2003). For the initiation of differentiation, progenitor B cells interact with
stromal cells via c-kit on B cells and stem cell factor (CD117) on the stromal cells. This
interaction induces the release of interleukin (IL)-7, which is necessary for the initiation of the
immunoglobulin (Ig) gene rearrangement. First, the heavy (H) chain variable (V) and
diversifying (D) segments are joined, followed by the rearrangement of the joining (J)
segment to the VD segment (Bassing et al., 2002).
The rearrangement process is mediated by the enzymes recombination-activating genes
(RAG)-1 and RAG-2, which are involved in deoxyribonucleic acid (DNA) cleavage. Knocking
out RAG-1/2 results in a loss of B and T cells, as RAG is also involved in the rearrangement
of the T cell receptor. The cleavage of the DNA at the D-J junction (H chain) generates sites
for the random addition of so-called P-region nucleotides. At the cutting ends of the V-DJ
coding sequence, so-called N-region nucleotides are added by the enzyme terminal
deoxynucleotidyl transferase (TdT), further contributing to antibody diversity. As the cleavage
and addition of nucleotides is a highly complex process, many rearrangements cause non-
productive sequences with stop codons, leading to the rearrangement of the second
chromosome. In the case that also the second rearrangement is non-productive, B cells
undergo apoptosis. B cells with a correctly rearranged H chain express the Ig H chain with a
so-called surrogate light (L) chain. Pre-B cells then rearrange the L chain V and J segment of
either kappa or lambda L chain genes, again with the addition of P-region nucleotides at the
junction of the V-D gene segments and N-region nucleotides during the process of D-J
joining. Successful rearrangement of both H and L chain genes results in the surface
expression of IgM and IgD (B cell receptor, BCR) with several co-receptors (CD22, CD79,
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CD19, CD21). Only about 8% of the pre-B cells in the bone marrow rearrange their Ig chains
successfully and leave the bone marrow.
B cell diversity is generated by the use of multiple germ-line gene segments, the random
VDJ and VJ joining, the junctional flexibility and the addition of P- and N-region nucleotides.
After activation, B cells undergo proliferation and somatic hypermutation (chapter 1.1.2),
which further increases the diversity and the affinity of antibodies. As the rearrangement,
deletion and addition of nucleotides are random processes, also B cells expressing auto-
antibodies against self-antigens might are generated. To eliminate these auto-reactive
immature B cells, they undergo a first round of selection. If self-antigens expressed in the
bone marrow can crosslink membrane bound IgM on the B cells, these self-reactive B cells
will undergo apoptosis. After the selection, naïve B cells leave the bone marrow (Goldsby et
al., 2003). They have a short life span in the periphery in the absence of an antigen-induced
activation and die within a few weeks by apoptosis.
The differentiation of T cells is similar to the B cell differentiation, including the
rearrangement of the T cell receptor (TCR) genes, which also consists of V, D and J
segments. And, although both Ig and TCR rearrangement involve the RAG-1/2 enzymes, in
B cells only the Ig genes and in T cells only the TCR genes are rearranged. While B cell
development takes place in the bone marrow, progenitor T cells migrate to the thymus,
where they differentiate and undergo positive and negative selection (Goldsby et al., 2003).
Figure 1: B and T cell development. Both derive from hematopoietic stem cells and need similar
mechanisms and enzymes for the rearrangement of the Ig and TCR genes. B cell differentiation takes
place in the bone marrow, while progenitor T cells migrate to the thymus where they undergo
differentiation and positive and negative selection. Adapted from http://www.tmd.ac.jp
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1.1.2 B cell activation
Naïve B cells can be activated in two ways. Bacterial cell wall components such as
lipopolysaccharide (LPS) or high mitogen concentrations can activate B cells, regardless of
their antigenic specificity and without direct T cell contact. They crosslink membrane bound
IgM, providing a signal strong enough for B cell activation. However, most antigens cannot
crosslink IgM themselves but encounter B cells in lymphoid organs. B cells that specifically
recognize a given antigen via the BCR will internalize and process the antigen for
presentation on major histocompatibility complex (MHC)1 class II molecules on the cell
surface. Recognition of a presented antigen by the TCR of CD4+ T helper cells (TH cell)
provides a first signal for B cell activation. The second signal is provided by the interaction of
the CD40 molecule on B cells and CD40-ligand (CD154) on TH cells. The interaction of B and
TH cells results in the release of cytokines such as IL-2, IL-4 and IL-5 by TH cells and in the
expression of the corresponding receptors on B cells, which in turn supports B cell
proliferation and induces differentiation into plasma and memory B cells.
Once a B cell is activated, it either develops directly into an antibody-secreting cell or moves
to germinal centers in lymph nodes (Klein and Dalla-Favera, 2008). In germinal centers, B
cells proliferate rapidly. During the proliferation, B cells acquire single nucleotide exchanges,
small deletions and duplications in the variable regions of the rearranged Ig genes. This
process, termed somatic hypermutation, is important for the affinity maturation of activated B
cells. However, as these mutations can potentially generate either non-productive sequences
or auto-reactive Ig, B cells migrate as so-called centrocytes to the L zone of germinal centers
where they encounter follicular dendritic cells (FDC). FDC present antigen-antibody
complexes on their surface to the centrocytes. If a centrocyte does not recognize these
antigen-antibody complexes, it undergoes apoptosis and is removed by so called tingible-
body macrophages. As the amount of specific antigen presented by FDC is limited, only
centrocytes with high affinity receptors find their antigen and receive survival signals from the
FDC. The interaction with FDC is necessary, but not sufficient for their survival. Centrocytes
further need to interact with TH cells, including the CD40-CD154 interaction for survival. The
interaction with a TH cell additionally provides signals for class switching of the constant Ig
region. Class switching is important as each Ig isotype has distinct effector functions
                                                 
1 MHC is in humans called HLA (human leucocyte antigen): It is a protein complex that binds and
presents peptides to T cells. Most nucleated cells express MHC class I and can present antigens to
CD8+ T cells. MHC class II is constitutively expressed by professional antigen presenting cells and
presents antigens to CD4+ T cells.
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(Table 1). Centrocytes receiving the necessary surviving signals further mature into plasma
cells or memory B cells.
Table 1: Properties and biological activities of human Ig isotypes. Modified from Goldsby et al. (2003)
Class Form Specialty
IgM Pentamer
Initial antibody class, does not require class switch. Binds viral particles and
complement.
IgD Monomer Only expressed as surface, e.g. transmembrane Ig molecule
IgG Monomer Activates complement cascade as well as phagocytes
  IgG1 Monomer
Second most effective complement activator after IgG3, mediates
opsonization
  IgG2 Monomer Weak complement activator
  IgG3 Monomer Most effective complement activator,, mediates opsonization
  IgG4 Monomer
Cannot activate complement, mediates opsonization with intermediate
affinity for Fc (Fragment crystallizable) receptors
IgA Dimer
Mainly secreted in mucosa, gastrointestinal tract and tears. Inhibits
attachment of pathogens to mucosal cells.
IgE Monomer
Binds to Fc on basophiles and mast cells inducing degranulation. Accounts
for hypersensitivity reactions.
Plasma cells generally neither express surface Ig nor MHC class II, but secrete a high
amount of antibodies (Calame et al., 2003). The lifespan of plasma cells varies from days to
months. Long-lived plasma cells are primarily found in the bone marrow, secreting antibodies
that account for more than 80% of the serum antibody titer.
Memory B cells express antigen-specific, class switched surface Ig of different isotypes such
as IgG, IgA, and IgE. They are long-lived, even in the absence of an antigen, and do not
secrete antibodies. Upon a re-challenge, memory B cells rapidly proliferate and give rise to
clonally expanded plasma cells.
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Figure 2: Germinal center environment. Antigen-activated B cells enter the dark zone of germinal
centers, where they differentiate into centroblasts and undergo clonal expansion. During proliferation,
the process of somatic hypermutation induces changes in affinity of the Ig. Centroblasts then
differentiate to centrocytes and move to the light zone, where they are selected for improved binding
by FDC and TH cells. Centrocytes with unfavorable antibodies undergo apoptosis. After class-switch
recombination, centrocytes eventually differentiate into memory B cells or antibody-secreting plasma
cells. Adapted from Klein, U and Dalla-Favera R (2008).
1.1.3 The complement cascade
Antibodies play a major role in the defense of pathogens. Yet, they only mark their antigens
and have no enzymatic activity with few proposed exceptions (Ponomarenko et al., 2006). In
order to cause damage to the target tissue or organism, either phagocytes containing an Fc
receptor or components of the complement system are recruited.
Complement cascade proteins are synthesized mainly by liver hepatocytes, but also by
monocytes, macrophages, and epithelial cells of the gastrointestinal and genitourinary tracts.
Most components are synthesized as pro-enzymes, which are not active until proteolytic
cleavage. If an activated component does not react with the next component in the cascade,
it is short lived.
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The complement cascade can be initiated via three different pathways: the classical, the
alternative, and the lectin pathway (Goldsby et al., 2003). Eventually all three lead to the final
step of forming the membrane attack complex (Figure 3).
The classical pathway is activated by IgM and certain subclasses of IgG (Table 1). These
antibodies bind C1q, therefore activating C1r and C1s, which results in the hydrolysis of C4
to C4b and C2 to C2a. This results in the formation of the C4bC2a complex, called C3
convertase, as it converts the C3 pro-enzyme into an enzymatically active form C3b.
The lectin pathway is very similar to the classical pathway. Mannose-binding lectin (MBL)
binds to mannose residues on the surface of microorganisms. It structurally resembles C1q
and after association with MASP (MBL-associated serine protease) activates C4.
The alternative pathway is antibody independent. Low amounts of C3 spontaneously
hydrolyze giving rise to C3a and C3b. Normally, C3b is rapidly inactivated by sialic acid.
However, if C3b binds to foreign surface antigens such as bacterial cell wall or viral particles,
it is longer stable and initiates the activation of factor B. The complex C3b-factor B is
recognized by factor D and the factor B can be cleaved. The resulting C3bBb amplifies the
complement cascade due to its C3 convertase activity.
The generation of the C3 and C5 convertase results in the generation of C3a and C5a, so
called anaphylatoxins, which are involved in the inflammation and phagocyte recruitment,
and C3b and C5b. C5b recruits C6, C7, C8 and C9 to form the membrane attack complex
(MAC). This complex mediates cell lysis of microorganisms, viruses, erythrocytes, and
nucleated cells.
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Figure 3: Overview of the complement activation pathways. Three different activation steps (classical
(yellow), lectin (green) and alternative (blue) pathway) emerge to the generation of C3 and C5
convertase, which eventually leads to the formation of the membrane attack complex (MAC). The
MAC forms pores into the cell wall of pathogens inducing their lysis. The anaphylatoxins C3a, C4a and
C5b (red) mediate the inflammation and recruit phagocytes. The factor C3b (purple) plays an
important role in the formation of the C5 convertases. It further binds Fc receptors on phagocytes and
to pathogens, marking them for opsonization. Modified from Goldsby et al. (2003).
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1.2 Autoimmunity
Autoimmune diseases are the third most common category of diseases in industrialized
countries, following heart diseases and cancer (Rose, 2002). Many autoimmune diseases
start at young age and continue throughout life. Due to frequently chronic disease courses,
lifelong immunosuppressive or immunomodulatory treatment is required.
Two groups of autoimmune diseases are distinguished (Goldsby et al., 2003): organ specific
and systemic autoimmunity. In organ specific autoimmune diseases, the immune response is
directed against antigens present in one defined organ, whereas in systemic autoimmune
diseases, a broad range of target antigens present in several organs and tissues are
involved. In both groups, auto-reactive T and B cells are, to varying degrees, mediators of
tissue damage.
1.2.1 Mechanisms leading to autoimmunity
Autoimmunity is defined as a misdirected immune response against self-antigens. It is likely
that, much rather than one individual factor, the coincidence of a number of factors leads to
the development of autoimmunity.
Most self-reactive T cells are deleted during maturation. While a few cells escape the
negative selection, they may not necessarily support an autoimmune response (Rose, 2002).
T cells remain ignorant if the cognate antigen is only present in low abundance, or presented
by MHC in the absence of co-stimulatory signals. These T cells remain tolerant and become
deleted (Kamradt and Mitchison, 2001). However, pathogens have been proposed to break
down tolerance by molecular mimicry. If T cells encounter a pathogen expressing proteins
structurally or sequentially similar to self-antigens, these T cells become activated by the
pathogen. Due to the similarity of the pathogen with self-proteins, the T cells might response
not only against the pathogen, but also against self-antigens, which were previously ignored
(Benoist and Mathis, 1998).
Tolerance mechanisms for B cells are not as well understood as those for T cells.
Crosslinking of the BCR by self-antigens during B cell maturation interrupts the development
and leads to apoptosis. Further, continuous interaction of self-reactive B cells with their
cognate antigen results in an unresponsive status, finally resulting in the apoptosis of the B
cells (Wardemann and Nussenzweig, 2007). How B cells escape the selection is not clear.
Antibodies recognizing not only self-antigens but also pathogens have been described in
several neurological diseases, such as Syndenham’s Chorea, where antibodies derived from
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patients reacted with N-acetyl-β-D-glucosamine (GlcNAc), the immunodominant epitope of a
group A streptococcal carbohydrate. Lysoganglioside GM1 (lyso-GM1), a glycolipid of the
CNS, inhibited the binding of the human derived antibodies to GlcNAc, implicating molecular
mimicry. Further, the lyso-GM1 plays an important role in neuronal signal transduction and
the human derived antibodies were shown to increase a kinase activity important for signal
transduction (Lee and Levin, 2008). In most examples, molecular mimicry is only partially
due to linear peptides, but most importantly due to structurally related epitopes involving
peptides but also lipids, nucleic acids, carbohydrates and others. Certain drugs are
associated with autoimmune diseases (Rose, 2002): Penicillamine has been associated with
myasthenia gravis; hydrolazin can induce a lupus-like disorder. In these cases, ceasing the
drug often results in remission.
Genetic susceptibility influences the development of autoimmune diseases as well. There is
a familiar clustering of autoimmune diseases. Monozygotic twins have a higher concordance
rate to develop an autoimmune disease than dizygotic twins. In the case of a few
autoimmune diseases, the responsible genetic susceptibility was directed to a single gene
mutation. However, unknown factors modify the severity of the disease and not every
individual having the same mutation necessarily develops autoimmune disease (Rose,
2002). For most diseases, the genetic factors are still unknown and might comprise several
genes involved. Some are linked to distinct HLA molecules, but this might be due to
association with other factors such as tumor necrosis factor (TNF)-α  or complement
(Davidson and Diamond, 2001). In most, but not all, autoimmune diseases, females are more
frequently affected than males (Gleicher and Barad, 2007). The reason for this gender bias in
autoimmunity is not yet clear.
1.2.2 T cells, B cells and secreted factors damage tissue in autoimmunity
If a self-molecule becomes antigenic, it cannot be eliminated. Therefore, it induces an
ongoing activation of lymphocytes. Both, auto-reactive T cells and auto-antibodies can
damage tissue expressing auto-antigens. T cells, for example, release perforin or granzyme
B leading to cell death. Chemokines secreted by activated T cells attract leucocytes to
inflammatory sites, further escalating the inflammatory immune response and can also
directly damage cells within inflammatory foci. B cells can be activated through interaction
with TH cells, but also independent by a number of viruses and bacteria, resulting in the
secretion of auto-reactive antibodies and, like T cells, a number of pro-inflammatory
cytokines. Antibodies cause damage through the formation of immune complexes, activation
of complement, and labeling of targets for phagocytosis. T cells and auto-antibodies seem to
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act together in autoimmune diseases leading to tissue damage and the related functional
defects (Davidson and Diamond, 2001).
1.3 Multiple sclerosis
Multiple sclerosis (MS) is one of the most common chronic inflammatory diseases of the
CNS. It affects nearly two million people worldwide, first symptoms mostly occur during early
adulthood. The clinical course of MS is very variable and unpredictable, often leading to
severe neurological disabilities over time.
1.3.1 Clinical manifestation
MS is diagnosed according to the fulfillment of diagnostic criteria, as described by McDonald
et al. and further revised (Polman et al., 2005). These criteria predominantly aim at the
identification of disease dissemination in space and time as typically seen in MS. Magnet
resonance imaging (MRI) (Figure 4), and the presence of oligoclonal Ig (see chapter 1.3.4.2)
in the cerebrospinal fluid (CSF) are paraclinical tests used to further support the diagnosis of
MS.
Three main forms of MS can be distinguished (Sospedra and Martin, 2005): relapsing-
remitting MS (RR-MS) is characterized by relapses and remissions without worsening of the
disease (Figure 4, left panel). About 50% of RR-MS patients develop during later stages of
the disease secondary progressive MS (SP-MS). During this stage, an ever-worsening
neurological deficit accumulates even without relapses, though these may still occur (Figure
4, right panel). A small proportion of MS patients develop a disease without relapses but
slowly progressive worsening of neurological deficits (primary progressive MS, PP-MS). The
latent phases between the first manifestation of MS and further relapses can last several
years, and intervals between relapses vary within patients and within disease course. The
reasons for the differences between the individual disease courses are not yet clear. Patients
suffer from weakness, optic neuritis, ataxia and vertigo. In addition, muscle spasm, fatigue
and depression but also cognitive difficulties and psychiatric disturbances can occur, making
daily live for MS patients difficult.
During early phases, inflammatory lesions are the most pronounced pathological finding,
whereas progressive demyelination and axonal loss are prominent in later stages of the
disease (Figure 4).
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Figure 4: Multiple sclerosis. Disease score is indicated by the clinical scale EDSS (red line). With
disease progression, brain volume decreases (green line) and lesion load increases (blue line). Early
stages of the disease are characterized by a predominance of inflammation (left side), whereas with
disease progression demyelination and axonal loss is more pronounced (right side). Adapted from
Sospedra and Martin (2005).
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1.3.2 Treatment
As the cause of MS is not yet identified, there is no treatment targeting a causative factor.
Most therapies either modulate or suppress the immune system. Substances such as
corticosteroids alleviate and shorten relapse phases but do not influence the long-term
disease course. Interferon (IFN)-β1 (Avonex, Begaferon/Betaseron, Rebif) displays
pleiotropic effects and was, among others, shown to inhibit T cell proliferation and blocks
transmigration across the vascular endothelium. It may also modulate the activation of
macrophages and other antigen presenting cells (Zhang et al., 2002). Glatiramer acetate
(Copaxone) induces the proliferation and activation of a specific population of TH cells,
which enter the CNS and express anti-inflammatory and neuroprotective effects (Blanchette
and Neuhaus, 2008). Both IFN-β1 and glatiramer acetate have been used for a number of
years, have proven to be safe, reduce the frequency of new relapses by 30-40%, but their
effect on disease progression remains controversial (Goebels and Becher, 2008).
Mitoxantron, a cytostatic drug with potentially serious side effects is only used for highly
active MS, when IFN-β1 and copaxone fail. It is thought to suppress proliferation of
circulating lymphocytes, in particular of B cells, and to induce apoptosis in immunocompetent
cells including B cells, T cells and dendritic cells (Gold, 2008). Another group of drugs are
antibodies directed against different targets (Goebels and Becher, 2008). Natalizumab
(Tysabri) is the most recent drug approved for the treatment of MS. It is a monoclonal
antibody directed against an adhesion molecule (alpha 4 integrin), which is expressed on the
surface of immune cells. Natalizumab inhibits the trafficking of T and B cells from blood
vessels into the CNS and therefore modulates the inflammation in the CNS (Engelhardt and
Kappos, 2008). Other monoclonal antibodies are in different stages of preclinical or clinical
development. In particular, Rituximab, an antibody targeting CD20+ B cells has recently been
demonstrated to be highly effective in MS in a phase II clinical trial (Hauser et al., 2008).
Although none of the available drugs can cure MS, they are expected to prevent or delay
neurological impairment.
1.3.3 Etiology
The etiology of MS is largely unknown and as with other autoimmune disorders, multiple
factors may be involved in the immunopathogenesis of MS. Viral infections induced by
measles, rubella, varicella zoster and mumps viruses have been frequently discussed in the
context of MS, but so far only in the case of Epstein-Barr virus (EBV) there seem to be
substantial evidence. EBV-reactive oligoclonal Ig (see chapter 1.3.4.2) and CD8+ T cells
responses were more pronounced in MS patients than in controls (Cepok et al., 2005). EBV
infected B cells were shown to be present in the meninges of MS brain tissue (Serafini et al.,
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2007). However, since in Europe over 90% of the population is EBV infected, a causal link
between EBV and MS is difficult to verify.
Genetic studies showed that the prevalence of MS is increased in families with other
members affected by MS, whereas adopted relatives did not had a higher prevalence
(Dyment et al., 1997). Siblings have an increased risk and identical twins have a
concordance rate of 30%, indicating that genetic factors strongly influence the risk to develop
MS. The HLA locus, mainly HLA-DQ and HLA-DR, shows the strongest risk association in
genome wide linkage analyses for MS (Hillert and Olerup, 1993; Haines et al., 1998).
However, more than 200 genes are encoded in this locus including genes involved in various
immunological processes. Besides the HLA locus, other non-HLA genes were recently
associated with an increased risk to develop MS (Oksenberg et al., 2008), such as
polymorphisms in the IL2Ra or IL7R genes. However, the role of these candidate genes
needs to be further investigated.
Apparently, the incidence of MS has increased over the last centuries, especially in women.
Genetic risk factors cannot change over such a short time period; therefore, environmental
factors might contribute to the risk to develop MS. The prevalence of MS varies between
different regions around the world, being the highest in northern Europe, the middle part of
North America, and southern Australia (Noseworthy et al., 2000). Emigrants from an area
with a high MS prevalence to a low risk country before the age of 15 acquire the new, lower
risk , whereas migration after puberty does not seem to change the risk to develop MS
(Sospedra and Martin, 2005).
Figure 5: Prevalence of MS. Prevalence is highest in northern Europe, North America and southern
Australia and lower in Asia and South America. Adapted from www.atlasofms.org
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1.3.4 Pathogenesis
Hitological hallmarks of MS are sclerotic plaques or lesions in the central nervous system
(CNS). They are usually located in the white matter of brain and spinal cord, but recent data
also showed the presence of demyelinated plaques in the grey matter (Bjartmar et al., 2003;
Stadelmann et al., 2008). Demyelination is the most prominent feature in MS lesions, where
immune mechanisms are thought to lead to a destruction of both the myelin sheath and the
oligodendrocytes. The infiltration of T cells and B cells and activation of macrophages results
in cytokine secretion, further supporting inflammation and contributing to demyelination and
axonal degeneration (Figure 6) (Hemmer et al., 2002). Axonal transsection is a common
finding in MS lesions and may be the cause for an irreversible neurological impairment in MS
(Trapp et al., 1998). Our current understanding of how T cells and B cells induce the tissue
damage seen in MS is summarized in the following paragraphs.
Figure 6: Schematic view of the immune responses in MS: T and B cells are primed in the periphery
by antigens released from the CNS or by cross-reactive foreign antigens. Invading B cells might
maturate to plasma cells and secrete large amounts of Ig. Dendritic cells present neuronal antigens to
T cells, thereby strongly stimulating T cell proliferation. T cells encounting their antigen, secrete
inflammatory cytokines, which attract other immune cells to invade the CNS and thereby contribute to
the inflammation and injury of the CNS. Adapted from Hemmer et al. (2002).
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1.3.4.1 Role of T cells in MS and EAE
Experimental autoimmune encephalomyelitis (EAE), the animal model for MS, is induced in
susceptible animals either by active immunization with myelin antigens or by adoptive
transfer of myelin-reactive T cells (Paterson, 1960; Wekerle et al., 1994). Active
immunization induces a primarily CD4+ T cell dependent immune response, leading to CNS
demyelination and clinical signs suggesting CNS tissue damage. Therefore, a large part of
research in MS aimed to investigate the role of CD4+ T cells in MS (Hemmer et al., 2002).
However, CD8+ T cells are more frequent in MS lesions than CD4+ T cells (Lassmann et al.,
2007) and CD8+ T cells have been shown to be clonally expanded in MS patients, indicating
an antigen driven immune response, (Babbe et al., 2000; Skulina et al., 2004). Furthermore,
myelin specific CD8+ T cells have been shown to induce CNS myelin damage similar to that
observed in MS (reviewed by (Neumann, 2003)). Therefore, animal models using CD8+ T
cells are being developed, showing similar clinical signs as the EAE model mediated by
CD4+ T cells (Mars et al., 2007). In MS lesions, MHC class I antigens are expressed on
inflammatory cells but also on neurons and glial cells (Hoftberger et al., 2004). Inflammatory
signals such as IFNγ upregulate MHC class I expression, which may further increase the
susceptibility of axons to CD8+ T cell attacks (Hemmer et al., 2002). But, using MHC class I
light chain knockout mice, axons remained intact despite extensive demyelination (Rivera-
Quinones et al., 1998), indicating that the role of T cells is more complex than anticipated.
Taken together, there seem to be parallels between MS and EAE regarding T cell dependent
immune mechanisms. However, the fact that the overlap is incomplete may explain why
certain treatment modalities that showed promising results in EAE proved to be ineffective or
even detrimental to MS.
1.3.4.2  Role of antibodies in MS and EAE
The humoral response has been implicated in the pathogenesis of MS (Link, 1978). This
hypothesis is supported by the increased clonal production of Ig in more than 95% of MS
patients, which can be revealed by isoelectric focusing electrophoresis of MS CSF samples
(Figure 7).
The presence of these so-called oligoclonal Ig bands (OCB) in the CSF but not in the serum
of patients, as well as the presence of clonally restricted Ig gene products in lesions
(Baranzini et al., 1999) and clonally expanded B and plasma cells (Owens et al., 2003)
indicate an intrathecal, antigen-driven immune response. OCB are proposed to be produced
by clonally expanded CD138+ plasma cells (Obermeier et al., 2008). The OCB pattern of a
patient remains relatively stable during disease progression (Walsh and Tourtellotte, 1986),
suggesting that the CNS provides a long-term survival environment for plasma cells.
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In several chronic brain inflammation diseases such as subacute sclerosing panencephalitis,
rubella panencephalitis, or tuberculous meningitis, the OCB represent antibodies directed
against the causative agent (Gilden et al., 2001; Correale and de los Milagros Bassani
Molinas, 2002; Burgoon et al., 2006). The identification of the antigen specificity of the OCB
in MS patients remains to be one of the most outstanding challenges, which may help to
clarify underlying disease mechanisms in MS.
Figure 7: Isoelectric focusing electrophoresis of CSF (C) and serum (S). OCB are not detectable in
healthy patients (1). In MS patients (2), OCB are present in the CSF, but not in the serum, whereas in
patients with systemic infections (3), OCB are present in the serum and CSF. Adapted from
http://www.ii.bham.ac.uk/clinicalimmunology/Neuroimmunology/IEF.htm
Activated B cells can readily enter the healthy human brain; however, they can hardly be
detected in the CSF of healthy people. In contrast, in MS and other inflammatory
neurological diseases (OIND) there are increased numbers of CSF lymphocytes, and B cells
account for around 5% of the CSF cells.
In active MS lesions, chemoattractans such as CXCL12 and CXCL13 are upregulated,
attracting B cells to migrate through the leaky blood brain barrier into the CNS. Having
reached the brain, the inflammatory CNS provides an environment supporting B cell
maintenance (Serafini et al., 2004; Meinl et al., 2006). BAFF, one of the crucial survival
factors for B cell survival, is normally expressed by stromal cells in the bone marrow.
However, macrophages, monocytes, dendritic cells, and astrocytes in the CNS produce
BAFF (Schneider, 2005). In active MS lesions, BAFF expression even reaches even the
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same levels as in lymphatic tissue. Factors such as nerve growth factor, IL-6, and
hyaluronan (CD44 ligand) are also upregulated in the inflamed CNS supporting the survival B
cells (Meinl et al., 2006).
Most B cells in the CSF have a memory phenotype (CD27+), which is not the case in the
blood (Meinl et al., 2006). These memory B cells can be re-stimulated by T cells, or, following
bystander activation, be driven into proliferation and differentiation into Ig secreting plasma
cells. Studies on the Ig repertoire in the CSF and MS brain specimens support that B cells
undergo antigen-dependent proliferation and somatic hypermutation. Germinal center-like
structures have been described in the meninges of MS patients (Serafini et al., 2004; Serafini
et al., 2007), suggesting that an affinity maturation may take place in the CNS.
Antibody and complement deposits have been demonstrated to be present in active lesions
(Woyciechowska and Brzosko, 1977; Storch et al., 1998). Auto-antibodies against myelin
antigens have been detected in the CSF and peripheral blood of MS patients (Reindl et al.,
1999; Niehaus et al., 2000; Martin Mdel and Monson, 2007) and in areas of myelin
breakdown (Genain et al., 1999). Therefore, Ig may induce direct damage through
complement activation, or by activating macrophages and microglia via the Fc receptor on
those cells. However, myelin-specific antibodies can also be detected in the serum of healthy
controls (Karni et al., 1999; Kuhle et al., 2007). It has been suggested that pathogenic
antibodies against myelin oligodendrocyte glycoprotein (MOG) may recognize glycosylated
(Marta et al., 2005) or conformation dependent (von Budingen et al., 2004) epitopes.
Whether myelin specific antibodies in MS patients differ from antibodies in the serum of
control groups remains to be determined. Recent research suggests that not only myelin-
specific antibodies might be involved in the disease progression, but also antibodies directed
against neuronal proteins. Antibodies directed against neurofascin or neurofilament (NF) light
subunit have been isolated from CSF of MS patients (Silber et al., 2002; Mathey et al., 2007),
and a monoclonal antibody against neurofascin was shown to enhance disease severity and
induced axonal damage in EAE (Mathey et al., 2007).
Using adoptive transfer of encephalitogenic T cells, EAE can be induced in B cell deficient
mice (Wolf et al., 1996), indicating that B cells and antibodies are not absolutely required for
the development of EAE. Nevertheless, administration of anti-MOG antibodies leads to a
more severe disease score and/or significantly enhanced demyelination in rodents
(Schluesener et al., 1987; Piddlesden et al., 1993) and non-human primates (Linington et al.,
1988; Genain et al., 1995; Raine et al., 1999; von Budingen et al., 2004).
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1.3.5 Demyelination, remyelination and axonal loss in MS
MS is characterized by demyelination coinciding with relapses and remyelination, associated
with remission. Disease progression is believed to be related to the failure of remyelination
and enhanced axonal damage.
Spontaneous remyelination of axons occurs in MS lesions often coinciding with remission
phases (Arnold, 2007). Infiltrating cells release not only detrimental, but also beneficial
cytokines, which may promote the proliferation and differentiation of oligodendrocyte
precursor cells (OPC), and therefore support remyelination. Further, the clearance of myelin
debris by resident microglia or infiltrated phagocytes is thought to be beneficial for
remyelination (Raivich and Banati, 2004). Though, there are also factors present in MS
lesions inhibiting remyelination. Myelin debris itself can inhibit OPC differentiation (Kotter et
al., 2006) and proteins such as LINGO-1 negatively regulate oligodendrocyte differentiation
(Mi et al., 2005).
The loss of the myelin sheath and the loss of trophic factors secreted by oligodendrocytes
are thought to enhance axonal loss. Moreover, activated immune and glia cells in
inflammatory lesions secrete substances such as cytokines, oxidative products and
chemokines, which may additionally damage axons (Bjartmar et al., 2003).
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1.4 Organotypic slice cultures
To investigate the role of humoral and cellular components of the immune system, we
established an ex vivo model for immune mediated CNS damage using organotypic CNS
slice cultures (OSC). Two main techniques for long-term cultivation of OSC have been
described (Figure 8) (Stoppini et al., 1991; Gahwiler et al., 1997). The roller-tube technique
offers the advantage that the OSC flatten to a monolayer, which results in optimal optical
conditions and access to single neurons. Therefore, this technique is preferably used for
electrophysiological recordings. Cultures grown on membrane inserts remain thicker and the
three-dimensional structure is preserved. This method is mainly used to study interactions
between different cell types and only few groups studied the electrophysiological properties
of nerve groups (Stoppini et al., 1997).
Figure 8: Two methods for the long-term cultivation of OSC. The cultivation in roller-tubes (A) leads to
a flattening of the slices allowing optimal access to single neurons. Cultures grown on membrane
inserts (B) flatten less and the three-dimensional structure is better maintained. Adapted from
Gahwiler at al. (1997).
OSC of hippocampi have been widely used to study synaptic plasticity, epilepsy, and
neuronal pathways (Gahwiler et al., 1997). Demyelination and remyelination have mostly
been studied in aggregating cultures by the addition of myelin specific antibodies and
complement (Honegger et al., 1989; Matthieu et al., 1992; Roth et al., 1995; Diemel et al.,
2004). The addition of IFN-γ (Diemel et al., 2004) or protein kinase C activator (Pouly et al.,
1997; Pouly et al., 2001) has been described to induce myelin damage as well. In all studies,
demyelination was prominent, but the axonal integrity has not been addressed.
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Remyelination was repeatedly analyzed in aggregating CNS cell cultures (Matthieu et al.,
1992) and described to be enhanced by insulin, insulin like growth factor-1 (IGF-1) (Roth et
al., 1995) and transforming growth factor beta (TGF-β) (Diemel et al., 2004). Inhibition of cell
proliferation by cytosine arabinoside (AraC) also inhibited remyelination (Pouly et al., 2001).
Yet, in aggregating cell cultures, contacts between the dissociated cells have first to be
reestablished. On the contrary, in OSC the natural three dimensional cytoarchitecture and
the interactions between axons, neurons and astrocytes is preserved (Stoppini et al., 1991;
Gahwiler et al., 1997). The differentiation and maturation of the myelin sheath continues
during the cultivation period, which leads to a similar morphology of neurons and overall
tissue organization as in vivo (Gahwiler and Zimmer, 1986; De Simoni et al., 2003). As
myelination is dependent on contacts of OPC with axons and on factors secreted by axons
and astrocytes (Barres and Raff, 1999), myelination is enhanced in OSC compared to
cultures of aggregating CNS cells. Therefore, OSC seem particularly well suited to examine
processes of myelination in an ex vivo situation. They can be maintained in culture for
several weeks allowing for chronic treatment (McKinney et al., 1999).
Demyelination has also been induced in OSC, but only by the addition of lysolecithin
(Birgbauer et al., 2004), a chemical lipid widely used in animal models for demyelination. The
authors showed that lysolecithin as a demyelinating agent preserved axonal morphology and
that remyelination occurred in OSC. However, lysolecithin is a chemical lipid and might not
involve the same downstream pathways as involved in humoral mediated demyelination.
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1.5 Goal of this work
Prominent features indicating the involvement of the humoral immune response in MS are
the intrathecal production of clonally expanded Ig, detectable as OCB, and the presence of
antibody and complement deposits in MS lesions. Although the role of antibodies in the
pathogenesis of MS has not yet been clearly demonstrated (Hemmer et al., 2002), they could
exhibit disease-worsening effects. To further characterize the role of antibodies in MS, we
generated recombinant human monoclonal antibodies from MS CSF derived clonally
expanded plasma cells (cePC). The CSF used for this study was obtained for diagnostic
purposes from patients with early (clinical isolated syndrome, CIS) or clinically definite MS.
CSF plasma cells were single cell FACS (Fluorescence activated cell sorting) sorted and
cePC were identified according to the nucleotide sequence of the CDR3 region after single
cell reverse transcription polymerase chain reaction (SC-PCR) of immunoglobulin genes.
Subsequent recombinant expression of paired Ig H and L chains and reconstruction as
monoclonal antibodies (MS-mAb), allowed the investigation of their antigen, tissue specificity
and pathophysiological relevance. This approach was used since it has previously been
shown to faithfully reproduce the antigen specificity of antibodies from cePC (Burgoon et al.,
2006; Kuenzle et al., 2007).
To be able to investigate the effect of humoral immune mechanisms independently from the
contribution of the cellular immune effector arm, we established an experimental system
using OSC from transgenic mice expressing GFP in myelin (PLP-GFP). This system allowed
us to visualize live demyelination and remyelination. by the addition of a myelin specific
antibody of known demyelinating capability and complement and promised to be a suitable
readout for the evaluation of the pathophysiological relevance of the MS-mAb described
above.
Results part I
Clonally expanded plasma cells in the
cerebrospinal fluid of MS patients produce
myelin-specific antibodies
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2 Results
2.1 Recombinant antibodies derived from MS CSF plasma cells
We obtained 96 to 228 CSF plasma cells from the CSF of four patients with early (CIS) or
clinically definite MS (von Budingen et al., 2008). To identify cePC, we FACS sorted single
CD138+ plasma cells and subsequently performed SC-PCR of their IgG H and L chain genes
(Ritchie et al., 2004; von Budingen et al., 2008). Assembly of expressed IgG H chain variable
region genes in groups of identical sequences yielded information on 19 independent plasma
cell clones. For 9 of the 19 sequences, matching Ig L chain sequences were obtained (von
Budingen et al., 2008). PCR products of paired H and L chain genes from cePC were
recombinantly reconstructed and expressed in a eukaryotic IgG1 expression vector (MS-
mAb). This approach has been demonstrated to faithfully resurrect pathogen-specific
antibodies and to maintain the original antibody affinity (Burgoon et al., 2005; Kuenzle et al.,
2007).
Table 2: Patient Data and frequency of MS-mAb.
Patient Gender Disease Age at lumbar
puncture
Cell
count
Sorted
plasma cells
Treatment MS-mAb Frequency
of MS-mAb
BA F CIS 28 5/ul 96 none BA40 2/21
BA86 5/21
BA92 3/21
GS F RR-MS 29 20/ul 192 IFN-b1a GS6 13/57
GS36 5/57
MB M RR-MS 24 14/ul 228 none MB34 2/66
MB101 4/66
MB106 4/66
SU F SP-MS 48 3/ul 96 none SU61 4/24
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2.1.1 Staining on human MS brain specimen
Demyelination in CNS white matter is the most prominent neuropathological feature of MS
and is thought, at least in part, to be due to auto-antibody responses directed against myelin.
Therefore, we were interested whether our MS-mAb displayed myelin reactivity.
Immunofluorescence staining of 8 of the 9 MS-mAb on post-mortem human MS brain tissue
revealed myelin reactivity (Figure 9B). Double staining with a MOG-specific antibody (Figure
9C) and a proteolipid protein (PLP)-specific antibody (Figure 9D) further supported the
myelin reactivity, although none of the tested myelin specific antibodies showed a complete
overlap with any of the MS-mAb (not shown). The structures stained by the MS-mAb (red)
enfolded neurons (stained with the antibody SMI-32 specific for non-phosphorylated NF,
green) (Figure 9D), which again indirectly supports myelin reactivity. Importantly, neither a
control antibody produced in the same recombinant system (Figure 9I) nor purified human
IgG1 (not shown) used as negative control showed any reactivity with CNS tissue. Although
the MS-mAb strongly stained perilesional myelin in MS tissues, they revealed only rare
staining of myelin in healthy control brain tissue (Figure 9E), while staining for myelin basic
protein (MBP), PLP and MOG was preserved in both normal appearing white matter (NAWM)
of MS tissue and healthy control brain white matter tissue (Figure 10).
One of the antibodies (MS-mAb GS6) showed astroglial reactivity (Figure 9G), as shown by
co-staining with an antibody specific for glial fibrillary acidic protein (GFAP) (Figure 9H). The
staining intensity of the MS-mAb GS6 was comparable in MS tissue and healthy control (HC)
brain tissue (not shown).
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Figure 9: Myelin and astroglial reactivity of MS-mAb. A: Luxol fast blue stain of human MS brain tissue
(original magnification 50x, black frame: approximate localization of tissue sections shown in B-D and
F). B-I: Confocal micrographs of immunofluorescence stainings on human MS brain tissue (B-D and F-
I) or HC white matter tissue (E). B: SU61 (red). C: BA92 (red), anti-MOG antibody (green). D: BA86
(red), anti-PLP antibody (blue), anti-NF antibody (SMI-32) (green). E, F: GS36 (red), anti-MOG
(green). G: GS6 (red). H: anti-GFAP antibody (green). I: Isotype control antibody. Numbers above
white bars are µm. Adapted from von Budingen et al. (2008).
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Figure 10: Myelin staining by different antibodies on MS brain tissue (MS) and control tissue (HC).
Antibodies specific for MOG, MBP, and PLP (not shown) stain NAWM of MS tissue. Control brain
tissue (HC) was stained by all tested myelin reactive antibodies (MOG, MBP and PLP).
Interestingly, all myelin reactive MS-mAb showed a more pronounced staining of myelin at
the rim of MS lesions (Figure 11) compared to the lesion center, which contains undetectable
amounts of myelin and NAWM with intact myelin as shown by luxol fast blue staining or
immunostaining for myelin antigens (Figure 10).
Figure 11: Staining of myelin by MS-mAb is enhanced at the lesion border. Immunofluorescence
micrograph of MS white matter tissue stained with MS-mAb SU61. Enlargements of tissue sections
from within the demyelinated lesion, the lesion border and NAWM are shown to the right. Original
magnification 400x. Adapted from von Budingen et al. (2008).
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To test whether a similar myelin reactivity as detected with the MS-mAb could also be
detected in the original CSF of the MS patients, from which the MS-mAb were derived, we
performed staining of purified, biotinylated IgG from CSF of two different patients (BA and
SU). Purification and biotinylation of CSF IgG was necessary due to the high background
staining obtained on MS brain tissue when using anti-human Ig antibodies as secondary
reagents. While the CSF IgG of patient SU showed no reactivity for MS brain tissue at the
maximal possible concentration (10 µg/ml) (not shown), the CSF IgG of patient BA, used at a
concentration of 40 µg/ml, revealed a somewhat diffuse staining pattern containing features
reminiscent of staining with the MS-mAb from the same patient  (Figure 12). However, these
results remain still incomplete. Additionally, it has to be kept in mind that the absence of
myelin staining with CSF IgG may not at all correlate with the presence (or absence) of
plasma cells producing myelin reactive antibodies in this CSF since a) the myelin specific
IgG concentrations in the original CSF may result from low numbers of plasma cells and
therefore be undetectably low or b) the relevant antibodies had already been absorbed out of
the CSF to myelin structures of the patient the CSF was obtained from.
Figure 12: Staining of MS white matter tissue with purified, biotinylated IgG from CSF of patient BA.
IgG was purified by immunoaffinity over protein G sepharose beads and biotinylated. A) CSF-IgG
staining was revealed by streptavidin-Alexa594 (red), cell nuclei by Hoechst 33342 (blue). B) shows
secondary reagents only.
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2.1.2 Tissue specificity of MS-mAb
To identify potential tissue specificity of the MS-mAb, we tested their reactivity on different
non-CNS tissues. Specific staining could only be observed with the MS-mAb GS6. This
antibody stained, similar to the CNS tissue, filamentous structures in colon and lymph node
tissue (Figure 13). All other MS-mAb showed no reactivity against both tissues. Staining on
lymph node tissue revealed slight staining by all antibodies including purified human IgG1.
Therefore, we suggest that the IgG is bound by Fc-receptors present in the lymph node
tissue.
Figure 13: Staining of colon (C) and lymph node (LN) tissue. Representative immunofluorescence
micrographs of colon and lymph node tissue stained with MS-mAb GS6 and SU61 and human IgG1
as negative control. Original magnification 400x. Adapted from von Budingen et al. (2008).
2.1.3 Competition of the MS-mAb staining on human MS brain tissue
To confirm on the one hand the specificity of the MS-mAb staining and to obtain some
information about the recognized epitopes, we performed competition experiments with the
MS-mAb MB101 and MB106 versus themselves and all other MS-mAb. Unbiotinylated MS-
mAb was pre-incubated on MS brain sections over night before biotinylated MS-mAb MB101
or MB106 was added. Staining of biotinylated MS-mAb was revealed by streptavidin-
Alexa594. Both antibodies (MB101: Figure 15 and MB106: Figure 14) could displace
themselves, but no competition with any of the other MS-mAb was observed.
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Figure 14: Competition of MS-mAb MB106 versus itself and all other MS-mAb. MS lesion tissue was
pre-incubated with the indicated MS-mAb with the maximum possible excess (GS6, 150x; GS36,
160x; MB34, 800x; MB101, 60x; MB106, 190x; BA40, 180x; BA86, 130x; BA92, 90x; SU61, 600x)
prior to the addition of 10 µg/ml biotinylated MB106 (red staining). Under these conditions, MB106 was
only displaced by itself. Adapted from von Budingen et al. (2008).
Figure 15: Competition of MS-mAb MB101 versus itself and all other MS-mAb. MS lesion tissue was
pre-incubated with the indicated MS-mAb at 1000 µg/ml (100x excess) prior to addition of 10 µg/ml
biotinylated MB106 (red staining). Also MB101 was only displaced by itself not by any other MS-mAb.
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The competition experiments confirm the specificity of the MS-mAb and support that the MS-
mAb recognize different epitopes on CNS myelin. However, no conclusion can be drawn,
whether these epitopes are part of the same antigen or not. Further, it cannot be ruled out
that the MS-mAbs might indeed recognize the same antigen, but that displacement was
insufficient due to differences in affinity.
2.1.4 The MS-mAb do not bind to the usual suspects in FACS or ELISA
Auto-antibodies specific for myelin proteins like MOG and MBP have been detected in the
serum and CSF of MS patients (Genain et al., 1999; Niehaus et al., 2000; Martin Mdel and
Monson, 2007). Therefore, my laboratory colleague Hans-Christian von Buedingen tested
whether the MS-mAb bind to MOG and MBP. The MS-mAb showed no reactivity in enzyme
linked immunosorbent assay (ELISA) against purified human MBP, nor for recombinantly
expressed extracellular domain of human MOG produced in Escherichia coli (E.coli) (Figure
16B). Recent research has demonstrated that antibodies against glycosylated epitopes of
MOG possess myelin destructive potential (Marta et al., 2005). Therefore, we transfected
eukaryotic cells (Jurkat) with a plasmid coding for human MOG so that MOG would be
expressed in its glykosylated, correctly folded, extracellular form. We tested the reactivity of
our MS-mAb in FACS experiments, were no reactivity with this native MOG was found
(Figure 16A).
Figure 16: MS-mAb do not react with MOG nor with MBP. Panel A shows histograms of FACS
experiments with a eukaryotic cell line (Jurkat) transfected to express human MOG on its surface. The
humanized anti-MOG antibody (open histogram) showed a clear reactivity for MOG, whereas no
reactivity of any MS-mAb (here: BA86, light gray; identical findings for all other MS-mAbs, not shown)
or the isotype control (dark grey histogram) was observed. Panel B shows ELISA experiments
demonstrating the lack of reactivity with recombinant MOG and purified human MBP. Adapted from
von Budingen et al. (2008).
Virus specific antibodies were frequently detected in the CSF of MS patients and recent work
suggested that humoral responses against EBV to be a dominant feature of OCB (Cepok et
Results
-31-
al., 2005). Therefore, we had further tested the reactivity of the MS-mAb by the local clinical
virology laboratory for reactivity against seven common viruses (EBV, Cytalomegalo Virus,
Herpes Simplex Virus, Human Herpes Virus-6, measles, rubella, Varicella Zoster Virus)
suggested to be involved in MS. For none of the tested viruses, a specific reactivity was
observed (not shown).
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Result part II:
Remyelination after antibody-mediated
demyelination in an ex vivo model for
immune mediated CNS damage
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2.2 Antibody-mediated demyelination in OSC
Myelin specific antibodies have been shown to enhance the severity of EAE in both rodents
and non-human primates (Schluesener et al., 1987; Fierz et al., 1988; Linington et al., 1988;
Genain et al., 1995; Raine et al., 1999; Urich et al., 2006), to mediate demyelination in a
complement dependent fashion (Piddlesden et al., 1993; von Budingen et al., 2004), and to
induce - in combination with complement - demyelination in aggregating CNS cell cultures
(Notterpek et al., 1993; Loughlin et al., 1997). OSC have been used in chemical models of
demyelination (Birgbauer et al., 2004), but the role of antibody/complement-induced
demyelination has not been addressed.
We employed a MOG specific antibody (8-18c5) known for its complement mediated
demyelinating capacity. As shown by immunofluorescence staining for the myelin proteins
2',3'-cyclic nucleotide 3'-phosphodiesterase (CNPase, cyan), MOG (red) and MBP (purple),
addition of the anti-MOG antibody and complement induced a pronounced demyelination
(Figure 17A), whereas control OSC treated with an isotype control antibody and complement
showed no morphological changes (Figure 17B). To further semi-quantify myelin damage
with an independent method, we performed an ELISA specific for MBP, confirming our
findings: Treatment of OSC with the isotype control antibody alone (Figure 17C, black
column), in combination with complement (striped) or with the anti-MOG antibody alone
(white column) did not induce a significant loss of MBP. In contrast, the treatment with the
anti-MOG antibody and complement led to a highly significant (P < 0.001) decrease in MBP
content of OSC lysates (plaid column).
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Figure 17: Antibody/complement-mediated demyelination in OSC. Immunofluorescence stainings for
the myelin proteins CNPase (blue), MOG (red), and MBP (purple) document that the addition of the
anti-MOG antibody and complement (A) resulted in a loss of myelin, whereas control OSC treated with
an isotype control antibody and complement (B) showed no morphological changes. Scale bar,
200 µm. To quantify residual myelin, a sandwich-ELISA specific for MBP was performed (C). Identical
amounts of total protein extracted from OSC were added to anti-MBP coated wells and results were
normalized to treatment with isotype control antibody alone. MBP contents were similar in OSC
treated with the isotype control antibody alone (black column) or in combination with complement
(striped column), as well as in OSC treated with the anti-MOG antibody alone (white column). In
contrast, OSC treated with the anti-MOG antibody plus complement showed a marked reduction of
MBP content (plaid column). ***P < 0.001, n = 6. Results are displayed as mean ± standard error of
the mean.
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2.2.1 Kinetics of demyelination by confocal live imaging of PLP-GFP OSC
To analyze the process and the kinetics of demyelination in detail, we performed continuous
confocal live imaging using OSC from transgenic mice expressing GFP under regulatory
sequences of PLP (PLP-GFP OSC). Myelin damage started as early as two hours after
antibody and complement addition, first visible at the thin peripheral myelinated fiber
extensions of the cerebellar OSC (Figure 18A). Within 16 hours, these thin fibers were
completely demyelinated, coinciding with a gradual extension of the demyelination to the
thick central branches. In contrast, the morphology of control OSC did not change over the
indicated observation period (Figure 18B).
Figure 18: Confocal live imaging of demyelination in PLP-GFP OSC. Addition of the anti-MOG
antibody and complement induced demyelination, which was visible in thin peripheral myelinated
fibers as early as 2 hours after antibody/complement addition and gradually extended to the thicker
central branches over time (A). For a complete demyelination, a longer incubation period was
required. In untreated OSC (B), no morphological changes were observed over the whole confocal live
imaging period. Scale bar, 200 µm.
2.2.2 Axonal integrity is preserved after antibody/complement-mediated
demyelination
While demyelination is considered to be a potentially reversible event, axonal damage is
often viewed as the morphological correlate of persisting neurological impairment in MS
(Dutta and Trapp, 2007). While antibody/complement-mediated demyelination has previously
been demonstrated in aggregating CNS cell cultures (Diemel et al., 2004), the effect on
axonal integrity was not addressed.
OSC were treated for 48 hours with an isotype control antibody in combination with
complement (Figure 19A, A’), or with the anti-MOG antibody plus complement (Figure 19B,
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B’). As visualized by the anti-MBP staining, anti-MOG antibody/complement treatment
induced a pronounced demyelination (Figure 19B), while the incubation with isotype control
antibody/complement (Figure 19A) or anti-MOG antibody alone (data not shown) induced no
morphological myelin changes. Interestingly, despite being subjected to a demyelinated state
for 48 hours, axonal integrity of the anti-MOG antibody/complement treated OSC was as
unaffected (Figure 19B’) as the control OSC with intact myelin (Figure 19A’). This indicates
that a single event of antibody/complement-induced demyelination alone may not sufficient
for the axonal degeneration seen in MS lesions.
Figure 19: Axonal integrity is preserved after antibody/complement-mediated demyelination.
Treatment with isotype control antibody and complement (A) did not alter the morphology of
myelinated axons as demonstrated by staining for the myelin marker MBP (A) and the axonal marker
NF200 (A’). In contrast, addition of the anti-MOG antibody and complement induced striking
demyelination (B), whereas the axonal morphology remained intact (B’). Scale bar, 200 µm.
2.2.3 Combined anti-MOG and complement treatment causes massive
oligodendrocyte cell death
To gain insight in how demyelination affects oligodendrocyte survival, PLP-GFP OSC were
demyelinated in the presence of 2 µM propidium iodide (PI) for the detection of dead cells.
Interestingly, the highest number of PI+ cells was observed after 24 hours, when myelin
damage was already pronounced but incomplete (Figure 20A), whereas in OSC treated with
isotype control antibody and complement, only few cells were PI+ (Figure 20B). A
quantification of PI+ cells is shown in Figure 4C, documenting that anti-MOG
antibody/complement treatment resulted in a more than three fold increase in the number of
dead cells (P = 0.0003). Figure 20A’’ shows an enlarged overlay of PI+ nuclei (red) and GFP+
myelin (green), demonstrating that the majority of the PI+ cells are oligodendrocytes (arrows),
which is not the case in the control OSC (Figure 20B”). After complete demyelination (48
hours), few PI+ cells remained detectable (not shown), which – in combination with the
complete absence of detectable GFP as well as MBP, MOG, and CNPase staining (Figure
17) – strongly supports that oligodendrocytes were quantitatively eradicated.
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Figure 20: Anti-MOG antibody/complement treatment leads to extensive oligodendrocyte cell death.
PLP-GFP OSC were incubated with anti-MOG antibody and complement (A) or isotype control
antibody and complement (B) for 24 hours in the presence of 2 µM PI. Boxes in A/B define the regions
shown enlarged in A’’ and B’’. Cell death is visualized in A’ and B’ by PI+ nuclei (red) and quantified in
C. In A’’, an enlarged overlay of PI+ nuclei (red) and GFP+ myelin (green) is shown, demonstrating that
a substantial fraction of the PI+ cells consists of oligodendrocytes (arrows). Scale bar in A/B,
200 µm; Scale bar in A’’/B’’, 50 µm. *** P = 0.0003, n = 8. Results are displayed as mean ± standard
error of the mean.
2.3 Remyelination after antibody-mediated demyelination
Remyelination contributes to remission in MS patients in early disease stages, while, with
disease progression, remyelination is thought to fail (Patrikios et al., 2006). Until now, it
remains unclear whether insufficient recruitment or impaired differentiation of OPC is
responsible for this failure. Therefore, it might be helpful to develop methods or agents,
which enhance remyelination. Here, we analyzed the kinetics of remyelination after the
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complete destruction of oligodendrocytes and myelin mediated by humoral effector
mechanisms.
2.3.1 Live imaging of remyelination after antibody-mediated demyelination
Using live imaging of PLP-GFP OSC, we documented different stages of demyelination and
remyelination. Figure 21 shows confocal micrographs taken from the same slice before the
addition of antibody/complement (Figure 21A, 0 hours (h)), during demyelination (Figure 21A,
43 h), and during remyelination (Figure 21A, 53 h, 67 h, and 77 h). Interestingly, in spite of
the near complete demyelination we had induced (Figure 21A, 43 h), extensive spontaneous
remyelination (Figure 21A, 53 h – 77 h) was observed after removal of the detrimental
antibody and complement by exchange of culture medium. Remyelination began in the
vicinity of scattered oligodendrocyte nuclei and gradually extended to form a new network of
myelinated fibers (Figure 21A, 53 h – 77 h). In comparison, control PLP-GFP OSC treated
with an isotype control antibody and complement underwent only minor morphological
changes due to the incubation conditions (Figure 21B, 0 h – 77 h).
Figure 21: Confocal live imaging of remyelination. Micrographs of PLP-GFP OSC were taken before
treatment (A 0 h, B 0 h), during demyelination with the anti-MOG antibody and complement (A 43 h)
and during remyelination (A 53 h, 67 h, 77 h). Panel B shows images of control OSC incubated in
parallel with isotype control antibody and complement, taken at the same time points as images in
panel A. After removal of the anti-MOG antibody and complement, remyelination began in the vicinity
of scattered oligodendrocyte nuclei and gradually extended to form a new network of myelinated fibers
(A 53 h, 67 h, 77 h). OSC treated with isotype control antibody and complement (panel B) showed
only minor morphological changes due to the experimental setup. Scale bar, 50 µm.
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2.3.2 Remyelination is guided by morphologically intact axons
Only intact axons would be expected to provide guidance for remyelination. Accordingly, we
found that after antibody/complement-mediated demyelination (Figure 22A, A’), remyelination
exclusively occurred along morphologically intact appearing axons (Figure 22B, B’). Axonal
and myelin integrity was preserved in control OSC treated with an isotype control antibody
and complement (Figure 22C, D), and in OSC treated with the anti-MOG or isotype control
antibody without complement (not shown).
Figure 22: Remyelination is guided by morphologically intact axons. OSC were treated with the anti-
MOG antibody and complement (A, B) or with an isotype control antibody plus complement (C, D).
After an incubation period of 48 hours, OSC were either fixed (A, C) or further incubated for 10 days in
fresh culture medium (B, D). Strongly demyelinated OSC (A) spontaneously remyelinated (B) at sites,
where axons had remained morphologically intact (B’). The morphology of control OSC treated with an
isotype control antibody and complement was not visibly damaged (C, D). Staining for MBP is shown
in red, for NF200 in green. Scale bar, 50 µm.
2.3.3 OPC remyelinate naked axons after antibody/complement-mediated
demyelination
As remyelination is considered to be due to proliferation and differentiation of OPC, we
evaluated the presence of OPC after demyelination and during remyelination (Figure 23).
Staining for the OPC marker NG2 (Chondroitin sulphate proteoglycan NG2) (red) clearly
demonstrates that NG2 (chondroitin sulfate proteoglycan) positive cells are still present in
demyelinated OSC (Figure 23A), while their grid-like formation appears to be less
pronounced than in non-demyelinated OSC treated with an isotype control antibody and
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complement (Figure 23B). After removal of antibody and complement, slices were further
cultivated in the presence of bromodesoxyuridin (BrdU) for four days and stained with an
anti-BrdU antibody to visualize proliferating cells. Co-staining of OSC for NG2 and BrdU
clearly demonstrate the presence of proliferating OPC in previously demyelinated OSC
(Figure 23C), which further supports that remyelination is due to the survival, proliferation
and differentiation of OPC.
Figure 23: Oligodendrocyte precursor cells survive demyelination and proliferate during remyelination.
PLP-GFP OSC were treated with the anti-MOG antibody and complement (A, C) or with the isotype
control antibody and complement (B). OSC in A & B were fixed after 48 hours of treatment; OSC in C
were further cultured in the presence of BrdU for four days. Staining for the OPC marker NG2 is
depicted in red, for BrdU in blue. OPC are present after demyelination (A) and during remyelination
(C). Proliferating NG2 positive cells (arrows) are visualized by co-staining with BrdU (C). Scale bar,
200 µm in A & B; 50 µm in C.
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2.4 The Effect of MS-mAb on OSC
Having established an experimental system, which allows analyzing the effect of humoral
effector mechanisms without the influence of cellular immune components, we tried to further
evaluate the potential pathophysiological relevance of the MS-mAb in OSC.
2.4.1 Both, the murine and the humanized anti-MOG antibody efficiently induce
demyelination
To test whether the recombinant expression system we used to generate the MS-mAb with
the human Fc backbone, which is added by the expression vectors used, would influence the
demyelinating capacity of the resulting antibodies, we amplified the Ig genes from the
hybridoma cells which produce the mouse anti-MOG antibody (8-18c5) by PCR. We then
replaced the murine constant region genes of the H and L chain amplicons by human IgG1
and human kappa constant region genes and cloned, expressed and purified the resulting
“humanized 8-18c5” monoclonal antibody in the same way as the MS-mAb (Kuenzle et al.,
2007; von Budingen et al., 2008). The addition of the same complement concentration and
identical concentrations of the murine (Figure 24B) and humanized (Figure 24C) anti-MOG
antibodies both induced extensive demyelination of practically indistinguishable extent, in
contrast to treatment with complement and isotype control antibody (Figure 24A), where no
myelin damage was visible. These experiments establish that our modus of recombinant
expression does not significantly influence the demyelinating behavior of the resulting
antibodies. Previous experiments performed by my laboratory colleague S. Künzle also
confirmed that antigen specificity and affinity are preserved (Kuenzle et al., 2007).
Figure 24: Both, the murine and the humanized anti-MOG antibody efficiently induce demyelination.
Demyelination was induced by the addition of the same concentration of the murine anti-MOG
antibody (B) (hybridoma cell line) and the humanized anti-MOG antibody (C) (produced in 293T cells)
and identical complement concentration. Control slices were treated with a mouse isotype control
antibody and complement (A). After 48 hours, both myelin specific antibodies induced a similar extent
of demyelination in OSC, as visualized by MBP staining.
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2.4.2 Two out of nine MS-mAb stained myelin-like structures in mouse brain tissue
We then tested the reactivity of the MS-mAb to CNS tissue of healthy wild type mice.
Although some of the antibodies seemed to stain mouse brain tissue, only two of them
displayed myelin specific reactivity (Figure 25).
Figure 25: The MS-mAb SU61 and MB101 stain myelin-rich structures in mouse brain tissue. Mouse
brain cryosections were stained with the biotinylated MS-mAb SU61 (A) or MB101 (B) and with the
anti-MOG antibody (A’ & B’, green). Pictures were taken from the corpus callosum region. Original
magnification 400x.
2.4.3 Effect of MS-mAb on OSC
We then investigated the potentially destructive effect of the MS-mAb in combination with
complement in OSC. However, none of the MS-mAb antibodies induced visible
morphological changes, whereas the positive control (recombinant anti-MOG antibody hu8-
18c5) induced the expected demyelination (Figure 26, Figure 27, showing results obtained
by two different MS-mAb, representing similar outcomes of the other MS-mAb). To
circumvent potential differences in antibody affinities, we applied up to four times higher
concentrations of the MS-mAb than of the anti-MOG antibody but even these increased
antibody concentrations had no effect on the morphology of OSC.
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Figure 26: No visible demyelination was induced by the MS-mAb MB101 in combination with
complement. Myelin and neuronal structures were visualized with an anti-MBP antibody (red) and an
anti-NF200 antibody (green). Although marked demyelination was visible with the humanized anti-
MOG antibody (hu8-18c5), there were no morphological alterations if the MS-mAb MB101 was added.
Figure 27: The MS-mAb SU61 did not detectably affect the morphology of myelin or neurons. SU61
was added at a concentration of 120 µg/ml in combination with complement. Myelin and neuronal
structures were visualized by anti-MBP antibody (red) and anti-NF200 antibody (green) staining. Also
the MS-mAb SU61 did not induce any changes in the morphology of myelin nor of axons.
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2.4.4 Effect of MS-mAb on human brain biopsy tissue
As only two out of nine MS-mAb stained mouse brain tissue, which could be an explanation
for their inability to induce demyelination in mouse brain tissue, we attempted to induce
demyelination in human biopsy tissue obtained during neurosurgery. Surprisingly however,
not even the anti-MOG antibody 8-18c5 and complement (Figure 28D) could induce
morphological changes of myelin (Figure 28) or axons (not shown) compared to controls
(Figure 28A - C) in these human brain sections.
Figure 28: In human biopsy slices, no antibody/complement-mediated demyelination could be
induced. Human brain biopsy slices were left untreated (A), incubated with complement alone (B) with
the humanized anti-MOG antibody without (C) or with (D) complement for 4 days. No differences in
myelin morphology, as visualized by a staining for MBP (red) was observed. Scale bar, 50 µm.
As it turned out, the human brain tissue slices had a much denser texture than the OSC
derived from young mice, we therefore tested whether the lacking demyelination on human
slices could be due to an insufficient antibody penetration into the human brain tissue slices.
We incubated fixed human biopsy slices with antibodies against MBP, NF200 and GFAP in
the presence (Figure 29A) and in the absence (Figure 29B) of Triton X-100 for 4 days and
after washing secondary antibodies were applied. In both conditions, all three antibodies
stained the different structures within the human brain slices well and therefore must have
been able to penetrate the tissue.
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Figure 29: Staining of human brain biopsy slices with and without Triton X-100. Human brain biopsy
slices were fixed in 4% formaldehyde and either permeabilized with Triton X-100 (A) or not (B) and
stained for NF200 (NF, green), MBP (red) and GFAP (blue). Antibodies were able to diffuse through
the tissue, also in the absence of any permeabilizing agent (B).
We therefore conclude that not an insufficient tissue penetration of the antibodies impairs
demyelination and assume that other factors, such as the presence of complement inhibitory
proteins (Scolding et al., 1998) might be the reason for demyelination failure.
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2.5 Influence of macrophages on OSC
To investigate the role of macrophages in immune mediated CNS tissue damage, we
generated bone marrow derived macrophages and stimulated them with LPS. We then
applied the macrophages onto the slices in the presence or absence of the anti-MOG
antibody
Figure 30: Addition of macrophages to OSC does not induce CNS tissue damage. Unstimulated (left
panel) or stimulated (right panel) CFSE labeled macrophages were added in the absence (upper row)
or presence (lower row) of the anti-MOG antibody to the slices. After 48 hours, slices were fixed and
stained for MBP (red). No myelin damage induced by the macrophages with or without the anti-MOG
antibody was observed. Original magnification 200x.
However, we could not observe any myelin damage due to the addition of the macrophages
to the slices. We also used peritoneal macrophages, but also these macrophages induced no
visible damages to the myelin or axons (not shown).
2.6 Role of microglia in antibody mediated demyelination
Microglial cells have been proposed to exert both beneficial but also detrimental effects on
the interaction of the immune system with the CNS. To further elucidate the involvement of
microglia in the antibody/complement-mediated de- or remyelination process, we depleted
microglia by the addition of ganciclovir to OSC derived from transgenic mice expressing the
herpes simplex virus tyrosine kinase (HSVTK) under a CD11b promotor (Heppner et al.,
2005; Falsig et al., 2008).
Treatment of the OSC with ganciclovir leads to a nearly complete depletion of microglial cells
(Figure 31B’). Surprisingly, the addition of the anti-MOG antibody with complement did not
induce any visible demyelination in these microglial deficient OSC, whereas control slices
Results
-48-
treated with ganciclovir but not expressing the HSVTK, were demyelinated, as expected
(Figure 31). Treatment with the isotype control antibody induced no morphological changes
in slices derived neither from CD11b-HSVTK positive nor from negative littermates (not
shown).
Figure 31: Microglia depletion impairs antibody/complement mediated demyelination in OSC. OSC
from CD11b-HSVTKxPLP-GFP transgenic mice (B) or CD11b-HSVTK negative littermates (A) were
treated with the anti-MOG antibody or the isotype control antibody and complement. As visualized by
the GFP expression in myelin (green) and staining for microglia (red), demyelination was induced in
OSC containing microglia (A), but not in OSC depleted from microglia (B). Micrographs in A”/B” show
an overlay of A/A’ and B/B’, respectively.
We are currently performing further experiments to find out whether microglia are important
for the removal of the myelin or which other role microglia may play and whether
reconstitution with peritoneal macrophages can restore the demyelination.
2.7 Phosphorodiamidate morpholino oligonucleotides as a tool to
temporarily downregulate specific gene expression in OSC
Phosphorodiamidate morpholino oligonucleotides (PMO) are DNA analogons widely used in
Zebrafish and in tissue culture to downregulate the expression of proteins of interest
(Nasevicius and Ekker, 2000). In addition, they can also be injected into mice and have been
used to induce alternative splice variants (Alter et al., 2006). Interestingly, in vivo, injection
into the animal is sufficient for the delivery of PMO into the target cells, whereas in vitro PMO
have to be complexed with lipids to facilitate their penetration into cells. Moulton et al. have
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shown that crosslinking PMO to the Tat-peptide offers an alternative delivery method into the
cell (Moulton et al., 2004). PMO are currently being tested in clinical trials for their potential to
ameliorate various diseases such as cardiovascular diseases, cancer, and viral diseases
(AVI Biopharma).
We investigated, whether PMO can also be used for the downregulation of proteins of
interest in OSC, e.g. in order to reduce the amount of proteins known to inhibit remyelination.
To establish this approach in our OSC system, we crosslinked a PMO specific for GFP with
different crosslinkers and different “penetrating” peptides as published (Moulton et al., 2004).
As shown in Figure 32, the crosslinked GFP-PMO downregulated GFP signal to about 30%
as determined by FACS (not shown).
Figure 32. Addition of a GFP-specific PMO downregulates GFP expression in tissue culture. The
lissamine (red) labeled PMO was crosslinked to the peptide R9F2C. Green cells still express GFP to a
visible degree, whereas in cells stained red by the uptake of the lissamine labeled PMO, GFP
expression was strongly downregulated.
PMO have not yet been used in OSC of brain tissue and only one technical report described
the application of PMO in kidney organ cultures (Nikopoulos et al., 2008). We next tested the
efficiency of different crosslinkers and peptides to find the best delivery system for PMO in
OSC. By using transgenic mice expressing a fusion protein of Period2 (Per2) and luciferase
(Period2:Luciferase), we visualized the downregulation of the luciferase activity by the
inhibition of the transcription of Per2. Although Per2 is a clock-gene, the expression of which
cycles during the day, in culture the synchronized clock-gene expression is lost after a few
days. Nonetheless, to further exclude any non-PMO related differences of Per2 expression
due to the clock gene regulation, luciferase activity was always measured at the same time
of the day. As shown in Figure 33D, only crosslinked Per2-specifc PMO efficiently reduced
the luciferase activity, whereas the GFP specific PMO, used as a control PMO, had no effect
on the luciferase activity. The red staining of the OSC caused by the lissamine labeled PMO
demonstrates that both PMO penetrated the slices to a similar extent (Figure 33 A-C). Per2-
specific PMO crosslinked with different linkers to either the HIV peptide TAT or to an artificial
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peptide (R9F2C) similarly downregulated luciferase signaling, whereas not crosslinked Per2-
specficic PMO had no effect on luciferase signal (not shown).
Figure 33: Treatment of OSC from Period2:Luciferase transgenic mice with PMO specific for Per2
induced a marked decrease in luciferase expression. OSC from transgenic mice expressing a fusion
protein of Per2 and luciferase were treated with PMO specific for Per2 (A, D, square points), GFP (B,
D, triangle points), or were left untreated (C, D, ball points). Penetration of PMO into OSC is visualized
in red, as PMO are crosslinked to lissamine (A, B). D) Luciferase activity was measured at the
indicated days of treatment with PMO at the same time of day to circumvent possible artifacts due to
circadian differences of Per2 expression. Treatment with the PMO against Per2 induced a marked
decrease in luciferase activity (D, blue line), whereas it was the same in control treated OSC (D, red &
green line).
Our data show that PMO can be used to efficiently downregulate proteins of interest. We
further incubated the OSC in the absence of PMO for 7 days for recovery, but we did not
observe a normalization of luciferase activity. This could be either due to the high amount or
the long-lasting effect of the PMO added. Recovery after treatment is of interest as in the
treatment of patients a transitional downregulation is often desired. Further experiments will
be performed to determine the kinetics of PMO induced reduction of gene expression.
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Pathogen specificity and autoimmunity are distinct features of
antigen-driven immune responses in neuroborreliosis.
Kuenzle S*, von Büdingen HC*, Meier M, Harrer MD, Urich E, Becher B, Goebels N.
*SK and HCVB contributed equally
INFECTION AND IMMUNITY, Aug. 2007, Vol. 75, No. 8, p. 3842–3847
Neuroborreliosis (NB) is a chronic infectious disease of the central nervous system (CNS)
caused by a tick-borne spirochete, Borrelia burgdorferi. In addition to direct effects of the
causative infectious agent, additional immunity-mediated mechanisms are thought to play a
role in the CNS pathology of NB. In order to further understand the involvement of humoral
immune mechanisms in NB, we dissected the intrathecal antibody responses down to the
single-plasma-cell level. Starting with single-cell reverse transcription (RT)-PCR of
fluorescence-activated cell sorter-sorted cerebrospinal fluid plasma cells from an NB patient,
we identified expanded clones and resurrected the antigen specificity of their secreted
antibodies through recombinant expression of the correctly paired immunoglobulin H and L
chain genes as monoclonal antibodies (MAbs). As expected, we found specificity for the
causative infectious agent, B. burgdorferi, among the clonally expanded plasma cell (cePC)-
derived MAbs. However, from an independent cePC of the same patient, we could derive
MAbs specific for human CNS myelin, without detectable cross-reactivity with B. burgdorferi
antigens. While reactivity against B. burgdorferi is a known feature of humoral immune
responses in NB, we show (i) that immune responses specific for self-antigens may be a
distinct feature of CNS infections independent of pathogen reactivity and (ii) that humoral
autoimmunity in NB (since found in cePC) is the result of a truly antigen-driven immune
response. Our findings indicate that in NB mechanisms may be at play that induce distinct
immune responses specific for pathogen and self-antigens independent from "molecular
mimicry."
Thesis author work: I performed and helped with the immunofluorescence experiments.
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Clonally expanded plasma cells in the cerebrospinal fluid of MS
patients produce myelin-specific antibodies
Von Büdingen HC*, Harrer MD*, Kuenzle S*, Meier M and Goebels N
*HCVB, MDH and SK contributed equally
Eur. J. Immunol. 2008. 38: 2014–202
Clonally expanded plasma cells (cePC) and their presumed products, oligoclonal
immunoglobulin G bands (OCB), are characteristic findings in the cerebrospinal fluid (CSF)
of patients with multiple sclerosis (MS). While cePC and OCB strongly suggest an
involvement of B cell-dependent immune mechanisms in the pathogenesis of MS, their
actual pathological relevance and target antigens remain unknown. To further understand the
potential role played by cePC, we generated a panel of monoclonal antibodies (MS-mAb)
from CSF-derived cePC from four patients with early or definite MS. Single-cell RT-PCR of
correctly paired H and L chain immunoglobulin genes from individual cePC ensured the
subsequent resurrection of their original antigen specificity. Immunofluorescence stainings of
MS lesion tissue with MS-mAb revealed myelin reactivity in the cePC repertoire of all four
patients and intracellular filament reactivity in one patient. While myelin staining by MS-mAb
was only rarely detectable in non-MS CNS white matter tissue, it was greatly enhanced at
the edge of demyelinating lesions in MS brain tissue. Our findings provide conclusive
evidence for the presence of an antigen-driven B cell response in the CSF of MS patients
directed against epitopes present in areas of myelin degradation.
Thesis author work: I produced some of the MS-mAb, performed the immunofluorescence
and competition experiments, and transfected and selected the Jurkat cells for MOG
expression.
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Remyelination after antibody-mediated demyelination in an ex vivo
model for immune mediated CNS damage
Harrer MD, von Büdingen HC, Stoppini L, Alliod C, Pouly S, Fischer K and Goebels N
Submitted
Multiple sclerosis (MS) is the most common chronic inflammatory disease of the central
nervous system (CNS), often leading to severe disability. Demyelination, axonal damage,
mononuclear cell infiltrates and deposits of immunoglobulin and complement are
neuropathological hallmarks of MS lesions. The presence of oligoclonal immunoglobulins in
the cerebrospinal fluid of most MS patients suggests an involvement of antibodies in the
pathogenesis of MS. However, which mechanisms are most relevant for the demyelination
and axonal loss observed in MS lesions is poorly understood. Furthermore, conditions
promoting or inhibiting myelin repair after demyelination are not fully understood. To study
the contribution of the humoral immune response to demyelination and to explore the
regenerative abilities of demyelinated CNS tissue, we established an experimental system
using organotypic cerebellar slice cultures from mice with or without transgenic expression of
GFP (green fluorescent protein) under regulatory sequences of proteolipid protein. The
addition of a demyelinating monoclonal antibody specific for myelin oligodendrocyte
glycoprotein and complement induced complete myelin destruction and oligodendrocyte loss,
as demonstrated by confocal live imaging and staining for different myelin proteins.
Interestingly, in spite of the extensive demyelination, axons remained morphologically intact,
indicating that trophic disturbances induced by a single event of antibody/complement-
mediated demyelination are insufficient to cause axonal loss as seen in MS lesions. After
removal of antibodies and complement, pronounced remyelination occurred, presumably
originating from surviving oligodendrocyte precursor cells. We demonstrate in a close-to-in
vivo system that antibody and complement alone are sufficient for extensive myelin damage.
Furthermore, axonal guidance remains intact for extensive remyelination after removal of the
destructive effectors.
Thesis author work: All experiments were performed by myself. Contributions from
coauthors comprise help in establishing parts of the experimental system, the production of
antibodies and preparation of the manuscript.
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Confocal live imaging reveals direct transsection of myelinated
axons by antigen-specific CD8+ T cells
Sobottka B, Harrer MD, Ziegler U, Becher B, Hünig T, Goebels N
 Submitted
Deciphering the mechanistic underpinnings of demyelination and axonal damage in multiple
sclerosis is of fundamental interest. Using confocal live imaging we demonstrate here that
antigen-specific CD8+ T cells are capable of directly transsecting myelinated axons in
organotypic brain slices. Our results indicate that axonal loss is the result of “collateral
damage” induced by antigen-specific CD8+ T cells primarily targeting antigen-presenting
oligodendrocytes.
Thesis author work: I introduced BS into the techniques of OSC preparation, OSC and T
cell cultivation and manipulation, and live imaging. I studied the role of CD4+ T cells, which
were not inducing any damage and are not shown in the paper (BS repeated the
experiments). Further, I discussed the results with BS.
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4 Discussion
In my thesis, I addressed two main topics: 1) I analyzed the tissue specificity of recombinant
antibodies derived from clonally expanded CSF plasma cells from patients with multiple
sclerosis (MS-mAb) to further understand their possible involvement in the
immunopathogenesis of MS. 2) Using OSC from PLP-GFP transgenic mice, I established an
experimental system, which allows the visualization of the effect of different immune effector
mechanisms on CNS tissue by confocal live imaging. Applying this experimental system, I
characterized antibody mediated demyelination and remyelination and analyzed the effect of
the recombinant antibodies derived from MS patients described in 1).
4.1 Recombinant antibodies from clonally expanded CSF plasma
cells (cePC) of MS patient bind to myelin structures
Although antibodies are a prominent feature in MS, their role in the immunopathogenesis of
MS is still unclear. Previous studies have described that antibodies in the CSF of MS patients
are directed against myelin {Niehaus, 2000 #28;Reindl, 1999 #186;Sun, 1992 #255;Sun,
1991 #254} and suggested that OCB are the product of clonally expanded plasma cells
{Obermeier, 2008 #177}. OCB have been shown to specifically react with the causative
agents in infectious CNS disorders (Gilden et al., 2001; Correale and de los Milagros
Bassani Molinas, 2002; Burgoon et al., 2006) and EBV reactivity of OCB has been
suggested by Cepok et al. (2005). To further investigate antibodies expressed by cePC, we
single-cell sorted CD138+ plasma cells from four MS patients with different disease courses
(Table 2). We performed SC-PCR of expressed Ig genes and were able to identify 19
clonally expanded Ig H chain V region sequences, all containing mutations compared to the
germline sequence, indicating that they had undergone affinity maturation and were the
products of an antigen driven immune response. Some groups of H chain V regions with the
same complementarity determing region 3 (H-CDR3), contained infrequent interspersed
mutations, further indicating that these plasma cells underwent somatic hypermutation and
therefore strengthening the role of the CNS as an environment supporting antigen-driven
affinity maturation. For nine of the clonally expanded H chains, we obtained the
corresponding L chain sequences. After cloning them into expression vectors containing
sequences coding for a human IgG1 backbone, we expressed and purified nine different
recombinant monoclonal antibodies from expanded CSF plasma cell clones of four different
MS patients (MS-mAb) (Table 2).
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We tested the binding of the nine MS-mAb to MS lesion tissue to get insight into their tissue
reactivity. Eight of the nine MS-mAb showed a clear CNS myelin reactivity in MS tissue,
while one reacted with astroglia (Figure 9). The staining of the myelin-reactive MS-mAb was
most pronounced at the rim of MS lesions (Figure 11), whereas in non-MS brain tissue
staining was very weak. This indicates that the expression of the cognate antigens of the
MS-mAb is either induced or upregulated at the rim of MS lesions or that they are better
accessible due to the inflammatory damage. Myelin reactivity was not restricted to a few MS-
mAb, but was present in all four randomly chosen patients, independent of the disease
course and treatment. Myelin reactivity was even found in a patient with optic neuritis (CIS),
which is deemed to be a very early form of MS.
Having identified myelin reactivity of the MS-mAb, we were interested whether they displayed
reactivity for common antigens of the CNS, such as MOG, MBP or PLP. We observed no
reactivity with MOG, neither expressed as recombinant protein in E. coli nor expressed on
the surface of a stably transfected eukaryotic cell line (Jurkat) (Figure 16). No reactivity was
found against MBP purified from human brain (Figure 16). As purified PLP is difficult to
obtain, we performed immunofluorescence co-staining of MS-mAb with an anti-PLP antibody;
here, no exact co-localization was observed (Figure 9D).
Although eight of nine MS-mAb displayed a myelin specific staining pattern, indicating that
the antibodies may recognize the same antigen, we cannot further support this hypothesis.
On the contrary, our competition data, demonstrating that staining of individual MS-mAb was
only inhibited by the same and not by other MS-mAb (Figure 14, Figure 15), suggest that
different epitopes within CNS myelin are targeted. While we were able to confirm the
specificity of MS-mAb binding by self-competition, no definite conclusion can be drawn,
whether the epitopes recognized by MS-mAb are part of the same antigen(s) or not.
While the staining patterns of the MS-mAb are reproducible, neither Western blot analysis
nor immunoprecipitation experiments provided further insights into the exact antigens
recognized by the antibodies (data not shown, work performed by my colleagues S. Künzle
and H.-C. von Büdingen). It is possible that the epitopes recognized by the MS-mAb depend
on their conformation or on posttranslational modifications. Furthermore, lipids, which have
been described to be a potential target in MS (Mata et al., 1999; Menge et al., 2005), cannot
be appropriately represented by Western blot techniques. In collaboration with Ed Hogan
(Georgia, USA), we are currently investigating the reactivity of the MS-mAb with different lipid
antigens.
One of the MS-mAb showed reactivity against astroglia. Although to date no primary immune
response against astroglia has been described in MS, tissue breakdown in inflamed CNS
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white matter could also lead to the release of astroglial antigens and therefore stimulate an
immune response.
Clonally expanded plasma cells in the CNS could stem from CNS resident germinal centers,
as recently described (Serafini et al., 2004). On the other hand, cells of the B cell lineage
could cross the blood brain barrier or they could be derived from precursor cells residing in
the CSF. The role of antibodies in the immunopathogenesis of MS may include primary
demyelinating activity. However, antibodies could potentially serve a scavenging activity in
an environment in which inflammation and myelin breakdown results in cellular debris.
Further research will be required to clarify the role of antibodies in MS.
In summary, this data demonstrate that, within repertoires of antigen-driven antibody
responses in the CSF of MS patients, reactivity with myelin epitopes is a prominent feature
and should encourage further research to identify the targets of the humoral autoimmune
response in MS.
4.2 Antibody-mediated demyelination in OSC
OSC have been used in a chemical model of demyelination applying lysolecithin (Birgbauer
et al., 2004), in which the authors showed that lysolecithin induces widespread
demyelination, but leaves axons intact. However, lysolecithin as a chemical agent might not
induce the same downstream pathways as those involved in demyelination mediated by
humoral immune effector mechanisms. As antibodies directed against myelin components
have been detected in the blood, CSF and in the brain tissue of MS patients (Genain et al.,
1999; Niehaus et al., 2000; Martin Mdel and Monson, 2007), we investigated whether myelin
specific antibodies and complement alone could lead to the structural CNS damage seen in
MS. We treated OSC derived from transgenic mice (PLP-GFP), which express GFP in the
cytosol and membranes of oligodendrocytes (Spassky et al., 1998; Spassky et al., 2001,
personal communication B. Zalc ), with an anti-MOG antibody (8-18c5) of known
demyelinating activity and complement. Applying confocal live imaging (Figure 18), we
visualized for the first time the rapid changes in myelin morphology. Degradation was first
visible in thin peripheral nerve fibers and gradually extended to the thicker central branches
of the cerebellar OSC, eventually leading to a complete loss of myelin (Figure 18A). Myelin
morphology of control OSC showed no changes (Figure 17 - Figure 20). By addition of PI, we
demonstrated that myelin destruction was paralleled by the eradication of oligodendrocytes
(Figure 20). We suggest that oligodendrocyte cell death is induced by the formation of the
membrane attack complex, as it was demonstrated for a spinal cord demyelination model (Mi
et al., 2005). We did not further elucidate how oligodendrocytes are removed during the
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demyelination process. Microglia present in OSC (Dusart et al., 1997) may be responsible for
engulfing and removing the myelin debris. Taken together, we conclude that the presence of
myelin specific antibodies and complement is sufficient for demyelination as seen in MS
lesions.
4.2.1 Axonal integrity is preserved after antibody/complement-mediated
demyelination
Most damaged axons are found in and around MS lesions, but also in the NAWM due to
Wallerian degeneration. Mostly, axons are damaged while neuronal cell bodies seem to be
spared (Grigoriadis et al., 2004). Axonal damage is considered to be one of the main causes
of permanent neurological impairment (Dutta and Trapp, 2007). Several mechanisms may be
involved in axonal damage. While there is a positive correlation between inflammation and
axonal damage, it is unclear, whether immune cells directly damage axons or whether
released cytokines are responsible for the damage (Grigoriadis et al., 2004; Dutta and Trapp,
2007). In addition, loss of axons is visible in chronic demyelinated lesions with little or even
without signs of an ongoing inflammation (Bjartmar et al., 2003). Therefore, solely the loss of
the protective myelin sheath and associated trophic changes may induce or promote axonal
damage. By demyelinating OSC with antibody and complement, we showed that in spite of
extensive demyelination and oligodendrocyte loss, axons remained morphologically intact
(Figure 19). These findings imply that a single event of demyelination is not sufficient to elicit
axonal damage. Nonetheless, extended periods of active demyelination might render axons
more susceptible to bystander damage by cytokines or cellular immune components, which
are also present at sites of inflammation in MS lesions. Additionally, neuron-specific
antibodies, like the recently detected neurofascin specific antibodies in MS patients (Mathey
et al., 2007) and antibodies against NF light chain subunit (Silber et al., 2002), may
contribute to the damage of neuronal structures (Huizinga et al., 2008).
In addition, T cells are assumed to play an important role in the MS pathogenesis. We
therefore further investigated the role of T cells in OSC. Interestingly, the addition of
activated CD4+ T cells had no impact on the morphology of OCS. However, the addition of
OVA-specific CD8+ T cells, prestimulated with the cognate antigen, indeed induced myelin
and axonal damage (Sobottka et al., submitted) when the cognate antigen was present in the
OSC. We propose that a single event of antibody/complement-mediated demyelination may
not be sufficient for the induction of axonal damage, but might render axons susceptible to
collateral damage induced by components of the inflammatory environment.
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4.2.2 MS-mAb in OSC
To further evaluate the pathophysiological relevance of antibodies in MS, we generated MS-
mAb (von Budingen et al., 2008) as described above (4.1). We stained normal mouse brain
tissue with the MS-mAbs, demonstrating that only two antibodies (SU61 & MB101) displayed
mouse myelin reactivity (Figure 25). Nevertheless, we tested the potentially destructive
properties of all MS-mAb in combination with complement on OSC. None of the MS-mAb
caused visible morphological changes of myelin or axons in OSC (Figure 26 - Figure 27), not
even at up to 4-fold higher concentrations than used for the anti-MOG antibody. As most of
the MS-mAb seem to specifically recognize human antigens, we also applied MS-mAb
together with complement onto slice cultures generated from human biopsy tissue obtained
during neurosurgery. Only a few groups published research using adult human slice cultures
(Jung et al., 2002; Gorji and Speckmann, 2004; Dorr et al., 2005). We used a similar system
as Jung et al. and tested the effect of the MS-mAbs, using the humanized anti-MOG antibody
as positive control. Unfortunately, not even the anti-MOG antibody induced any
demyelination in this tissue (Figure 28). Until now, we were not able to evaluate the cause of
the failure of demyelination. While we could show that antibodies can readily penetrate the
tissue (Figure 29), the presence of complement inhibiting proteins may be one reason for the
lack of demyelination (Funabashi et al., 1994; Scolding et al., 1998).
Further research is needed to investigate the role of the MS-mAb, including experiments
evaluating a potential beneficial role of the antibodies as suggested by some groups in
various models for MS. In contrast to the 8-18c5 anti-MOG antibody, other antibodies against
oligodendrocytes were shown to promote remyelination in a virus induced demyelination
model (Pirko et al., 2004). Antibodies specific for NogoA have been found in the serum and
CSF of MS patients (Reindl et al., 2003). These antibodies may harbor a beneficial role as
active vaccination with NogoA protein as well as passive vacciniation with NogoA specific
antibodies reduced EAE scores (Karnezis et al., 2004). A beneficial function of the MS-mAbs
could be tested either by adding them during remyelination in OSC or by injection into EAE
mice before or during the disease.
4.3 OSC as a tool to identify detrimental antibodies
CSF of patients with PP-MS or with RR-MS with a poor recovery induced axonal damage in
a primary neuronal culture model, whereas CSF of RR-MS patients with a good recovery did
not induce any neuronal damage (Alcazar et al., 1998, 2000). While in the above-mentioned
studies only axonal damage was addressed, others (Kim et al., 1970; Grundke-Iqbal and
Bornstein, 1980; Xiao et al., 1996; Cid et al., 2004) have suggested that serum or CSF of MS
patients induced demyelination and oligodendrocyte cell death, but they did not compare
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different MS courses. It would be interesting to compare the detrimental effect of CSF from
patients with different disease courses, and at different disease stages – ranging from early
to definite MS. Further, the effect of different treatments on the antibody repertoire would be
worth to be investigated. Such data might be used to predict the further course of the
patients’ disease as well as the effectiveness of treatment.
4.4 Remyelination in OSC
Remyelination is thought to be similar to developmental myelination, and CNS myelination is
thought to be related to myelination in the periphery. Myelination requires several steps
(Simons and Trajkovic, 2006): First, myelinating cells have to recognize axons and make
contact to them. Only then, myelin components are synthesized and transported to the axon,
which initiates the wrapping of the oligodendrocyte membrane around the axon. Finally, the
myelin sheath becomes compacted. Most of these processes are poorly understood and
available data derive mostly from Schwann cells, which myelinate axons of the peripheral
nervous system (PNS). Schwann cells derive from neuronal crest cells, which develop to
immature Schwann cells before birth. These immature Schwann cells encircle first groups of
nerves and during radial sorting, individual cells migrate away. In the end, one Schwann cell
myelinates one axon. Only large axons are myelinated, whereas small axons are surrounded
by nonmyelinating Schwann cells. Further, the amount of expressed neuregulin1 type III on
the axonal surface defines the thickness of the myelin sheath (Nave and Salzer, 2006).
Overexpression of neuregulin1 leads to hypermyelination, whereas down-regulation leads to
thinner myelin sheath or complete loss of myelination in the case of a knockout. Besides the
role in defining the myelin sheath thickness, neuregulin1 is also an important survival factor.
Oligodendrocytes, the myelinating cells of the CNS, arise from multiple foci along the neural
tube. In contrast to Schwann cells, oligodendrocytes myelinate multiple axons, forming up to
40 separate myelin segments. Which factors regulate the myelination by oligodendrocytes is
not clear, but axons are thought to release attractant and repellent signals for myelination
similar to the axons in the peripheral nervous system.
Remyelination has been correlated with remission phases in MS patients (Bruck, 2005;
Stadelmann and Bruck, 2008). Employing the unique live imaging opportunities provided by
the transgenic GFP expression in myelin, we followed the process of de- and remyelination
in the same OSC. We showed that extensive spontaneous remyelination takes place after
removal of anti-MOG antibody and complement by exchange of culture medium. We
observed that remyelination was initiated by several oligodendrocytes, forming a scattered
network (Figure 21). It seems that remyelination was guided by morphologically intact axons
(Figure 22) surviving the antibody/complement-mediated demyelination. The presence and
Discussion
-62-
proliferation of OPC (Figure 23) in tissue quantitatively eradicated of mature
oligodendrocytes during the process of demyelination, led us to the conclusion that
remyelination of the naked axons originates from differentiating OPC, which were not
affected by the anti-MOG treatment.
Our findings are in line with previous reports suggesting that remyelination is due to the
proliferation and differentiation of OPC (Miller and Mi, 2007). Also in the adult human brain,
OPC are present. OPC isolated from human adult white matter have been differentiated into
mature oligodendrocytes in vitro (Armstrong et al., 1992), suggesting that also in the adult
human brain OPC may divide and migrate to sites of demyelination and therefore facilitate
remyelination.
OSC provide an excellent tool to study substances important for remyelination.
Oligodendrocyte cell proliferation is increased by progesterone (Ghoumari et al., 2005), IL-11
(Zhang et al., 2006) and platelet derived growth factor (Woodruff et al., 2004). However,
Woodruff et al. showed that enhancing the absolute number of OPC is not sufficient to
enhance remyelination. This suggests that successful strategies to enhance remyelination
should be directed to an efficient maturation of OPC rather than to enhance their proliferation
rate. One of the discussed factors to promote OPC differentiation is IGF-1. In vitro, it has
been described to increase OPC differentiation (Roth et al., 1995; Mason et al., 2000),
whereas in vivo data are still controversial (Cannella et al., 2000; Luzi et al., 2004).  We
tested the effect of IL-11 to promote remyelination as described for OPC culture (Zhang et
al., 2006). However, by using the medium supplemented with serum, no differences with or
without the addition of IL-11 were observed. Medium supplemented with IL-11 only was not
sufficient for survival and remyelination (not shown). IL-11 is either not as potent as
suggested or several factors are needed for survival and remyelination of OSC. Preliminary
data suggest that the addition of the Insulin-Transferin-Selenium A supplement to serum free
medium provides at least survival of OSC, whereas it is not sufficient for remyelination (not
shown). We suggest that OSC in a medium sufficient for survival could be used to test the
remyelinating potential of candidate substances, before going into the living animal. Cultures
of OPC alone could be used to test the responsiveness of oligodendrocytes but they are not
sufficient for the complex system of brain cells to test substances beneficial for remyelination
or inhibiting demyelination.
Interestingly, antibodies, which under certain conditions are strong mediators of myelin
destruction, have also been demonstrated to promote remyelination.
Mice treated with serum IgG from donor mice hyperimmunized with homogenized spinal cord
before the induction of EAE, had an improved clinical score and enhanced remyelination
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(Rodriguez and Lennon, 1990). Monoclonal antibodies with remyelinating properties were
generated from humans and vaccinated mice (Miller et al., 1994){Pirko, 2004 #211}. While
we have so far been unable to demonstrate remyelinating or restorative properties of our
MS-mAb, such a hypothesis is highly attractive and further research is needed to clarify this
point.
4.4.1 The origin of remyelinating cells
The origin of remyelinating cells is not completely clear. On the one hand, surviving
oligodendrocytes could account for remyelination. However, in our antibody/complement-
mediated demyelination system, oligodendrocytes are quantitatively eliminated (Figure 17 -
Figure 20), therefore, we suggest that there are no surviving oligodendrocytes, which could
induce remyelination. On the other hand, most authors suggest that remyelination is due to
the proliferation of OPC. We showed that OPC are present and proliferate during
remyelination in OSC (Figure 23) indicating that in OSC the differentiation of OPC accounts
for remyelination. In vivo, possibly both account for remyelination. Demyelination in MS
lesions is often not as complete as in OSC and therefore surviving oligodendrocytes could
regenerate and remyelinate intact axons. OPC present in lesions become activated and start
to proliferate and differentiate (Zhao et al., 2005). Further, OPC might be recruited from non-
damaged areas into demyelinated lesions, where they proliferate and differentiate into
myelinating oligodendrocytes (Blakemore and Keirstead, 1999).
We observed that remyelination takes place exclusively around morphologically intact axons.
Thus, the reduction of axonal numbers observed in later stages of MS is expected to
interfere with remyelination. In turn, remyelination is beneficial for axonal survival, as recently
suggested in a cuprizone-induced animal model of demyelination (Irvine and Blakemore,
2008). OPC were depleted by irradiation leading to an impaired remyelination and an
increased axonal degeneration, whereas reconstitution of the irradiated mice with OPC from
a donor mouse enhanced remyelination.
4.4.2 Failure of remyelination
In general, remyelination is successful in MS patients (Patrikios et al., 2006). Nevertheless,
remyelination often fails with disease progression. Inflammation and recruitment of OPC
often coincide, and as a result differentiating OPC might be destroyed and the source of
OPC might be exhausted (Blakemore and Keirstead, 1999; Niehaus et al., 2000; Kotter et al.,
2006). The formation of the glial scar during disease progression might also impair the
migration of OPC. Moreover, OPC maturation might be inhibited by factors such as PSA-
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NCAM (Charles et al., 2002; Lubetzki et al., 2005) or LINGO (Miller and Mi, 2007). Therefore,
we established PMO for the downregulation of proteins inhibiting remyelination. PMO
efficiently penetrate tissue in vivo, however in vitro they need to be complexed with lipids or
crosslinked to peptides to facilitate tissue penetration (Moulton et al., 2004). To establish the
system, we used OSC from transgenic mice expressing a fusion protein of
Period2:Luciferase (Yoo et al., 2004). Using a PMO specific for Per2, a clock gene, allowed
us to quantify downregulation of Period2 by measuring luciferase activity. To circumvent
artifacts due to possible circadian changes in protein expression induced by clock genes,
luciferase activity was always measured at the same daytime. We used different crosslinkers
as well as two different peptides to determine which PMO modification would give the best
tissue penetration. Only the PMO specific for Per2, but not the GFP specific PMO
downregulated luciferase activity (Figure 33D), although both penetrated the tissue to a
similar extent (Figure 33 A-C). In contrast to Moulton et al., we did not observe major
differences using the different peptide/crosslinker combinations (not shown). Having now
established PMO suitable for the downregulation of distinct proteins, this method could be
used to downregulate inhibitors of remyelination and repair such as NogoA and LINGO-1.
4.4.3 Role of microglia
Microglia are thought to play a dual role during inflammation (Neumann et al., 2008). Via toll
like receptors, microglia recognize and remove pathogens, which induces an inflammatory
response by secretion of cytokines such as TNFα, IL-1 or the production of nitric oxide.
Under normal conditions, microglia have highly ramified processes, which are motile and
monitor the status of the local surrounding. Upon encountering debris of apoptotic cells,
microglia phagocyte without the induction of an inflammatory response, probably even
secreting anti-inflammatory cytokines such as TGF-β  and IL-10. We are currently
investigating the role of microglial cells in the process of antibody/complement-mediated
demyelination. Preliminary data show, that in the absence of microglia, demyelination
appears strongly reduced (Figure 31). Whether the myelin is damaged but not removed or
which other roles microglia are displaying is currently under investigation.
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5 Materials and Methods
5.1 Patients, cerebrospinal fluid and plasma cell sorting
Upon receiving informed consent from each patient, we obtained 7-10 ml of CSF during a
spinal tap intended for diagnostic purposes. The study was approved by the local ethics
committee. Immediately after collection, CSF was centrifuged for 10 min at 400 g, 4 °C and
the supernatant was carefully removed. CSF cells were resuspended in 250 µl FACS buffer
(PBS, 2% (v/v) fetal calf serum) and incubated with FITC-labeled anti-human CD138
monoclonal antibody (AbD Serotec, Duesseldorf, Germany) at 4 °C for 30-60 min. Single
CD138+ plasma cells were sorted on a FACS-Aria (Becton Dickinson, Allschwil, Switzerland)
into individual wells of 96-well PCR plates, each containing 20 µl of RT reaction buffer and
stored at -80 °C until further processing.
5.2 Single Cell RT-PCR and antibody cloning
Single cell RT-PCR was performed using reverse primers specific for the constant regions of
Ig genes (H, lamda and kappa chain) and forward primers specific for the conserved
framework region 1 of all H or L chain Ig variable region families, as described (Owens et al.,
2003; Kuenzle et al., 2007; von Budingen et al., 2008).
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Table 3: Primer used for single cell RT-PCR:
Sense primer H chain
VH17-F CAG GTG CAG CTG GTG CA(AG) TCT GG
VH2-F CAG ATC ACC TTG AAG GAG TCT GG
VH35-F GAG GTG CAG CTG GTG (GC)AG TCT GG
VH3a-F GAG GTG CAG CTG (GT)TG GAG TCT GG
VH4-F CAG GTG CAG CTG CAG GAG TCG GG
VH4a-F CAG GTG CAG CTA CAG CAG TGG GG
VH6-F CAG GTA CAG CTG CAG CAG TCA GG
Antisense primer H chain
CHG1 Owens GTT GTC CAC CTT GGT GTT GCT GG
Sense primer lamda L chain  
VL1-F GAGTCTGTSBTGACGCAGCCGCC
VL3a-F TCCTATGWGCTGACWCAGCCAC
VL38-F TCCTATGAGCTGAYRCAGCYACC
VL1459-F CAGCCTGTGCTGACTCARYC
VL78-F CAGDCTGTGGTGACYCAGGAGCC
VL15910-F CAGCCWGKGCTGACTCAGCCMCC
VL3B-F TCCTCTGAGCTGASTCAGGASCC
VL2-F CAGTCTGCCCTGAYTCAGCCT
VL6-F AATTTTATGCTGACTCAGCCC
Antisense primer lamda L chain  
CL1 Owens TGAACATTCTGTAGGGGCCAC
Sense primer kappa L chain  
VK1-F GACATCCRGDTGACCCAGTCTCC
VK36-F GAAATTGTRWTGACRCAGTCTCC
VK2346-F GATATTGTGMTGACBCAGWCTCC
VK5-F GAAACGACACTCACGCAGTCTCC
Antisense primer kappa L chain  
Ck1-Owens ACACTCTCCCCTGTTGAAGCTCTT
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Cells were lysed in 45 µl cell lysis buffer (33 µl H2O, 1 µl RNAse inhibitor, 2 µl NP40, 9 µl 5x
RT buffer). 20 µl of the lysed cells were transferred to new PCR tubes for the individual
amplification of IgG H, kappa or lamda L chain. mRNA was amplified using the appropriate
primers and an enzyme mix containing both reverse transcriptase and DNA polymerase
(OneStep RT-PCR Kit, Qiagen). RT-PCR was carried out in an Eppendorf Mastercycler at 50
°C for 60 min (RT) followed by 95 °C for 10 min, 45 cycles of 95 °C for 30 s, 58 °C for 30 s,
72 °C for 1 min and a final extension step of 10 min at 72 °C. PCR products were resolved
on 1.2% (w/v) agarose gels and appropriately sized PCR products were extracted using
MinElute Kit (QIAGEN) and sent for sequencing (Synergene Biotech, Switzerland). Ig
sequences from cePC were identified by assembling groups of identical variable region
genes (SeqMan, DNASTAR) and were further analyzed for germline segment usage and H-
CDR3 mutations via the V-Quest tool on the IMGT website (Giudicelli et al., 2004).
PCR cross-contamination was avoided by various precautions. Each PCR plate contained
wells, where no plasma cell had been sorted, serving as a negative control. The areas for the
PCR setup, PCR analysis by gel electrophoresis and cloning of PCR products are
designated spaces, physically separated and equipped with designated sets of pipetters. In
addition, fresh aliquots of PCR components were used for each patient’s CSF plasma cell
repertoire.
PCR products of cePC were cloned into vectors containing the constant region of IgG1, Igκ
or Igλ (kindly provided by H. Wardemann, Max-Planck Institut für Infektionsbiologie, Berlin,
Germany) as described (Wardemann et al., 2003). Briefly, restriction sites were introduced
using nested primers in a second PCR round. Digested products were gel-purified and
cloned into the corresponding expression vectors. Plasmids were sequenced to select clones
with inserts identical to the original PCR product.
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Table 4: Second round PCR primers containing restriction sites (bold) for cloning into the IgG1 H,
lamda and kappa vector, respectively.
Sense primer lamda L chain
5' AgeI Vl1 CTGCTACCGGTTCCTGGGCCCAGTCTGTGCTGACKCAG
5' AgeI Vl2 CTGCTACCGGTTCCTGGGCCCAGTCTGCCCTGACTCAG
5' AgeI Vl3 CTGCTACCGGTTCTGTGACCTCCTATGAGCTGACWCAG
5' AgeI Vl4/5 CTGCTACCGGTTCTCTCTCSCAGCYTGTGCTGACTCA
5' AgeI Vl6 CTGCTACCGGTTCTTGGGCCAATTTTATGCTGACTCAG
5' AgeI Vl7/8 CTGCTACCGGTTCCAATTCYCAGRCTGTGGTGACYCAG
Antisenseprimer lamda L chain
3' XhoI Cl CTCCTCACTCGAGGGYGGGAACAGAGTG
Sense primer kappa L chain
5' Pan Vk ATGACCCAGWCTCCABYCWCCCTG
5' AgeI Vk 1-5 CTGCAACCGGTGTACATTCTGACATCCAGATGACCCAGTC
5' AgeI Vk 1-9 TTGTGCTGCAACCGGTGTACATTCAGACATCCAGTTGACCCAGTCT
5' AgeI Vk 1D-43 CTGCAACCGGTGTACATTGTGCCATCCGGATGACCCAGTC
5' AgeI Vk 2-24 CTGCAACCGGTGTACATGGGGATATTGTGATGACCCAGAC
5' AgeI Vk 2-28 CTGCAACCGGTGTACATGGGGATATTGTGATGACTCAGTC
5' AgeI Vk 3-11 TTGTGCTGCAACCGGTGTACATTCAGAAATTC
5' AgeI Vk 3-15 CTGCAACCGGTGTACATTCAGAAATAGTGATGACGCAGTC
5' AgeI Vk 3-20 TTGTGCTGCAACCGGTGTACATTCAGAAATTGTGTTGACGCAGTCT
5' AgeI Vk 4-1 CTGCAACCGGTGTACATTCGGACATCGTGATGACCCAGTC
Antisense primer kappa L chain
3' Ck 494 GTGCTGTCCTTGCTGTCCTGCT
3' BsiWI Jk1/2/4 GCCACCGTACGTTTGATYTCCACCTTGGTC
3' BsiWI Jk2 GCCACCGTACGTTTGATCTCCAGCTTGGTC
3' BsiWI Jk3 GCCACCGTACGTTTGATATCCACTTTGGTC
3' BsiWI Jk5 GCCACCGTACGTTTAATCTCCAGTCGTGTC
  
Vector Sequencing  
Ab-sense GCTTCGTTAGAACGCGGCTAC
3' IgG int (antisense) GTTCGGGGAAGTAGTCCTTGAC
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5.3 Antibody production and purification
293T human embryonic kidney fibroblasts (American Type Culture Collection, Molsheim
Cedex, France) were cultured in DMEM supplemented with 10% (v/v) ultra-low IgG FCS,
penicillin/streptomycin (100 U/ml and 100 µg/ml, respectively), 2 mM L-glutamine (all from
Invitrogen, Basel, Switzerland). Co-transfection of 293T cells with Ig H and L chain encoding
plasmid DNA was performed by calcium phosphate precipitation (Chen and Okayama,
1988). Thereafter, the cells were cultured in serum free DMEM supplemented with 1% (v/v)
Nutridoma-SP (Roche), penicillin/streptomycin (100 U/ml and 100 µg/ml, respectively), 2 mM
glutamine (all from Invitrogen, Basel, Switzerland). Supernatants were collected after 8 days
of culture.
The hybridoma cell line 8-18c5 (kindly provided by Dr. C. Linington, Glasgow, Great Britain)
was cultured in serum-free Hybridoma SFM medium supplemented with
penicillin/streptomycin (100 U/ml and 100 µg/ml, respectively) and 2 mM glutamine (all from
Invitrogen, Basel, Switzerland). Supernatants were collected after 7 days in culture.
IgG from supernatants (MS-mAb and 8-18c5) was purified by affinity chromatography over
protein G columns (Amersham Biosciences, Otelfingen, Switzerland)
Where desired, antibodies were biotinylated, using NHS-biotin (Sigma, Buchs, Switzerland)
following the manufacturer’s instructions.
5.4 Humanization of the murine mAb 8-18C5
To obtain a chimeric antibody with the variable regions specific for the MOG but with human
constant regions, the variable regions of H and L chain genes were amplified from 8-18c5
hybridoma cell mRNA using the following primers: 8.18c5-VH-FWD-AgeI 5’- CTG CAA CCG
GTG TAC ATT CCC AGG TTC AGC TGC AGC AG-3’; 8.18c5-JH-REV-SalI 5’-TGC GAA
GTC GAC GCT GAG GAG ACT GTG AGA GT-3’; 8.18c5-VK-FWD-AgeI 5’-CTG CAA CCG
GTG TAC ATT CGG ACA TCG AGC TCA CAC AGT CTC-3’; 8.18c5-VK-REV-BsiWI 5’-GCC
ACC GTA CGT TTG ATC TCG AGC TTG GTG CC-3’. PCR products were purified and
cloned into the appropriate expression vectors containing the constant regions (Kuenzle et
al., 2007; von Budingen et al., 2008).
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5.5 Purification of CSF IgG
CSF of patients stored at –80 °C was thawed on ice. Protein-G sepharose beads (GE
Healthcare, Glattbrugg, Switzerland) were washed with PBS and added to the CSF over
night at 4 °C on a rotating wheel. Beads were loaded on empty columns (Amersham
Bioscience, Otelfingen, Switzerland) and after washing with PBS eluted with 0.1 M glycine,
pH 2.5. pH of IgG was adjusted to pH 7 with 1 M Tris pH 8.8. Biotinylation was preformed
using NHS-biotin (Sigma, Buchs, Switzerland) following the manufacturer’s instructions.
5.6 Immunostaining of human tissue
Immunofluorescence stainings of brain tissue were performed on sections of frozen post-
mortem white matter tissue from 3 MS patients (HSB-2684, 51 year old female; HSB-2771,
64-year old female; HSB-3110 49 year old female) and one patient with amyotrophic lateral
sclerosis (ALS, 55 year old female) (human tissue was kindly provided by the Human Brain
and Spinal Fluid Resource Center). Control stainings were performed on frozen human colon
and lymph-node tissue (kindly provided by the NICHD Brain and Tissue Bank for
Developmental Disorders). Serial snap frozen brain samples from human brain white matter
were cut into 10 µm thick sections using a cryotome and collected on Superfrost glass slides.
The sections were air dried and stored at –20 °C until further use. Sections were fixed in 4%
(w/v) formaldehyde and permeabilized in 1% (v/v) Triton-X 100 in PBS. Sections were
blocked with 10% (v/v) normal goat serum, 0.2% (v/v) Triton-X 100 in PBS for 1 hour (h)
before endogenous biotin was inactivated using the Streptavidin/Biotin Blocking Kit
(Vectorlab). Biotinylated MS-mAb were used at a concentration of 10 µg/ml, diluted with 1%
(v/v) normal goat serum, 0.2% (v/v) Triton-X 100 in PBS. For negative controls, biotinylated
human IgG1 Isotype (Fitzgerald Industries International, Inc. Concord, MA, USA) was used
like the MS-mAb. Staining was performed over night at 4 °C. After washing with PBS,
secondary antibodies were added for 1 h at room temperature. Imaging of immunostained
slices was performed using a laser-scanning confocal microscope (SP2 or SP5, Leica,
Heerbrugg, Switzerland).
5.6.1 Antibodies for immunofluorescence stainings
The following primary antibodies were used: for oligodendrocytes: anti-CNPase (1:500) (2',3'-
cyclic nucleotide 3'-phosphodiesterase, mouse monoclonal clone 11-5B, MAB326, Millipore,
Zug, Switzerland), anti-MBP (1:300) (myelin basic protein, rat monoclonal clone 12,  AbD
Serotec, Duesseldorf, Germany), anti-MOG (5 µg/ml) (mouse monoclonal ms 8-18c5
hybridoma, kindly provided by Dr. C. Linington, Glasgow, Great Britain or humanized hu8-
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18c5 (Kuenzle et al., 2007)), rabbit anti-PLP (1:500) (Abcam, Cambridge, UK); for
oligodendrocyte precursor cells: anti-NG2 (1:500) (Chondroitin Sulfate Proteoglycan, rabbit
polyclonal, AB5320, Millipore, Zug, Switzerland); for axons: anti-NF200 (1:1600) (mouse
monoclonal N52, Sigma, Buchs, Switzerland), mouse anti-nonphoshorylated NF (1:1000)
(SMI-32, Covance,Princeton, NJ, USA); for astrocytes: rabbit anti-GFAP (1:500) (Sigma,
Buchs, Switzerland); for microglia: Isolectin GS-B4-Alexa-594 or 568 (1:500) (Invitrogen,
Basel, Switzerland); for proliferating cells: anti-BrdU (1:50)  (bromodesoxyuridin, rat
monoclonal clone BU1/75(ICR1), AbD Serotec, Duesseldorf, Germany).
All secondary antibodies were obtained from Invitrogen, Basel, Switzerland. goat anti-human,
goat anti-mouse, goat anti-rat, goat anti-rabbit conjugated with Alexa-405, Alexa-488, Alexa-
568, Alexa-595, Alexa-633, as indicated. Secondary antibodies were used 1:700. To reveal
biotinylated antibodies, streptavidin Alexa-594 and Alexa-546 (1:1400) was used.
5.6.2 Competition-immunostaining experiments
For competition experiments, tissue was pre-incubated with the maximum possible excess of
non-biotinylated MS-mAb (competition of MB106: GS6, 150x; GS36, 160x; MB34, 800x;
MB101, 60x; MB106, 190x; BA40, 180x; BA86, 130x; BA92, 90x; SU61, 600x) or with 100-
fold excess of non-biotinylated MS-mAb (competition of MB101) at 4 °C overnight prior to the
addition of biotinylated MS-mAb at 10 µg/ml. After washing in PBS, bound biotinylated mAb
were detected with a strepatvidin-Alexa594 conjugate (1:1400; Invitrogen, Basel,
Switzerland). Imaging of immunostained slices was performed using a laser-scanning
confocal microscope (SP2 or SP5, Leica, Heerbrugg, Switzerland).
5.7 Testing MS-mAb for binding to MOG or MBP
For ELISA experiments, wells of polycarbonate plates (MaxiSorp, Nunc, Wiesbaden,
Germany) were coated with 1 pg/ml of a recombinant extracellular domain of human MOG
(rMOG, kind gift of M. Reindl, Innsbruck, Austria) or purified human MBP. Wells were
blocked with 3% (w/v) bovine serum albumin (BSA), in PBS containing 0.05% (v/v) Tween-20
(PBS-T). MS-mAb, humanized anti-MOG antibody or rabbit anti-MBP antibody (AbD Serotec,
Duesseldorf, Germany) were added at 10 µg/ml, CSF from all four patients were applied at
1:10 dilutions in blocking buffer and incubated for 1 h at 37 °C. Bound antibody was detected
with horseradish peroxidase-labeled anti-human or anti-rabbit IgG antibody (Jackson
Immunoresearch, Suffolk, UK), revealed by tetramethylbenzidine (Perbio Science, Lausanne,
Switzerland) and analyzed at 450 nm. For FACS analyses, Jurkat cells (kind gift of B.
Becher, Zurich, Switzerland) were stably transfected using Lipofectamine (Invitrogen, Basel,
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Switzerland) to express human MOG on their surface (plasmid kind gift of M. Reindl,
Innsbruck, Austria). MOG-transfected Jurkat cells were incubated with 10 µg/ml MS-mAb,
humanized anti-MOG antibody or human IgG1 isotype control for 10 min at 4 °C. After a
wash, cells were labeled with an anti-human IgG-APC conjugate (BD Biosciences, Allschwil,
Switzerland) and scanned in a FACS Calibur (BD Biosciences, Allschwil, Switzerland).
5.8 Animal husbandry
Mice were bred at the animal facilities of the University of Zurich under specific pathogen-
free conditions. Experimental procedures were approved by the Swiss Veterinary Office
(109/2006). Day of birth was designated P0. PLP-GFP transgenic mice were provided by B.
Zalc (Paris, France) (Spassky et al., 1998; Spassky et al., 2001). In these mice, GFP is
expressed under regulatory sequences and therefore located in the myelin sheath as well as
in the cytosol (personal communication B. Zalc). As PLP-GFP transgenic mice are
heterozygous, mice from the same litter could be used for live imaging and
immunofluorescence stainings. Both, mice with and without PLP-GFP transgenic expression
were used to obtain OSC as described in chapter 5.9.
MBP-OVA mice (Cao et al., 2006), expressing OVA under the MBP promoter, were kindly
provided by B. Becher (Zurich,  Switzerland). Period2:Luciferase mice (Yoo et al., 2004),
expressing a fusion protein of Period2 and luciferase were kindly provided by A. Fontana and
T. Birchler (Zurich, Switzerland). OSC of MBP-OVA or Period2:Luciferase mice were
prepared as described in chapter 5.9 and were used where indicated.
5.9 Organotypic CNS slice cultures (OSC):
OSC were prepared according to a modified protocol of a published method (Stoppini et al.,
1991). Briefly, the cerebellum was obtained from 8 to 10 day old pups and cut into 500 µm
thick slices using a McIllwain tissue chopper (GaLa Instrumente, Bad Schwalbach,
Germany). OSC were dissociated in ice-cold dissecting medium (Hank’s Balanced Salt
Solution (HBSS, Invitrogen, Basel, Switzerland) complemented with penicillin/streptomycin
(100 U/ml and 100 µg/ml, respectively, Invitrogen, Basel, Switzerland), 2.5 mg/ml glucose
(Sigma, Buchs, Switzerland) and 10 mM kynurenic acid (Sigma, Buchs, Switzerland)). The
OSC were cultured on Millicell-CM culture plate inserts (Millipore, Zug, Switzerland) in culture
medium (50% (v/v) MEM, 25% (v/v) HBSS, 25% (v/v) heat-inactivated horse serum, 2 mM
glutamine, penicillin/streptomycin (100 U/ml and 100 µg/ml, respectively) (all from Invitrogen,
Basel, Switzerland) and 2.5 mg/ml glucose (Sigma, Buchs, Switzerland)) for 4 days at 36 °C
in a humidified atmosphere with 5% CO2, and subsequently at 32 °C, 5% CO2.
Materials and Methods
-73-
5.10 Antibody/complement-mediated demyelination
Baby rabbit complement (Bioconcept, Allschwil, Switzerland) was reconstituted in
1 ml culture medium (50% (v/v) MEM, 25% (v/v) HBSS, 25% (v/v) heat-inactivated horse
serum, 2 mM glutamine, penicillin/streptomycin (100 U/ml and 100 µg/ml, respectively) (all
from Invitrogen, Basel, Switzerland) and 2.5 mg/ml glucose (Sigma, Buchs, Switzerland)).
The OSC were incubated with complement (the optimal concentration is dependent on the
complement batch and ranged from 3% (v/v) to 7% (v/v)) and 60 µg/ml antibody (8-18c5 or
mouse IgG1 isotype control antibody (Sigma, Buchs, Switzerland)) for 48 h at 32 °C in a
humidified atmosphere with 5% CO2. Where indicated, OSC were incubated with 2 µM
propidium iodide (PI, Sigma, Buchs, Switzerland) or 0.5 µM bromodesoxyuridin (BrdU,
Sigma, Buchs, Switzerland). Statistical analysis of PI+ cells was performed using unpaired
two-tailed Student’s t-test (GraphPad Prism version 4.02 for Windows, GraphPad Software,
San Diego, CA, USA).
5.11 Human brain biopsy slice cultures
Human brain tissue obtained during neurological surgery was kindly provided by K. Frei,
(Zurich, Switzerland). All procedures were conducted in accordance with the declaration of
Helsinki and approved by the ethics committee of the canton Zurich. Informed written
consent was obtained from all patients. Human brain tissue was cut into 200 µm thick slices
and cultivated on Millipore inserts in medium containing α-MEM, 10% (v/v) FCS, 1% (v/v)
Insulin-Transferrin-Selenium A supplement, 2.5 mg/ml glucose, 20 nM progesterone and 60
µg/ml of the indicated MS-mAb, anti-MOG antibody or isotype antibody. After 4 days in
culture, medium was replaced including antibodies and complement was added. Slices were
fixed after 4 days of treatment and stained as described for OSC.
5.12 MBP-ELISA
After washing with PBS, OSC from the same membrane were homogenized and sonicated in
triple detergent buffer (0.05 M Tris pH 8, 0.1% (w/v) SDS, 0.15 M NaCl, 0.01 M sodium
deoxycholate, 1% (v/v) Nonidet P-40, 0.02% (w/v) NaN3 (all from Sigma, Buchs,
Switzerland)) containing a protease inhibitor cocktail (Roche). Total protein content was
determined using the BCA Protein Assay Kit (Perbio Science, Lausanne, Switzerland).
Polycarbonate plates (MaxiSorp, Nunc, Wiesbaden, Germany) were coated with capture
mouse anti-MBP antibody (1:1000; MAB382, Chemicon/Millipore, Zug, Switzerland) in PBS,
and incubated overnight at 4 °C. Following three washes with washing buffer (PBS-T, PBS
containing 0.05% (v/v) Tween-20), non-specific protein binding was blocked by incubation
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with 5% (w/v) BSA in PBS-T for 1 h at room temperature. 10 ug homogenated protein was
added in duplicates and incubated overnight at 4 °C. After six washes with PBS-T, rabbit
anti-MBP antibody (1:300; 18-0038, Zymed/Invitrogen, Basel, Switzerland) was added for the
detection of bound MBP. Plates were incubated for 2 h at room temperature. For developing,
horseradish peroxidase-conjugated goat-anti rabbit antibody (1:9000; Jackson
Immunoresearch, Suffolk, UK) was added for 2 h at room temperature. Enzymatic activity
was revealed by tetramethylbenzidine (TMB, Perbio Science, Lausanne, Switzerland) and
analyzed at 450 nm. OD values were normalized to OSC treated with the isotype control
antibody alone. Statistical analysis was performed using one-way ANOVA with Bonferroni’s
multiple comparison post-test (GraphPad Prism).
5.13 Immunostaining of OSC
OSC were fixed in 4% (w/v) formaldehyde (Sigma, Buchs, Switzerland) in phosphate-
buffered saline (PBS) for 2 h at room temperature and permeabilized with 1% (v/v) Triton X-
100 (Sigma, Buchs, Switzerland) in PBS for 40 min. After three washes with PBS, OSC were
blocked for 1 h at room temperature with 10% (v/v) normal goat serum (Invitrogen, Basel,
Switzerland) in 0.2% (v/v) Triton X-100 in PBS. Primary antibodies were diluted in 1% (v/v)
goat serum, 0.2% (v/v) Triton X-100 in PBS and incubated for 2-3 days at 4 °C. OSC were
washed three times for 15 min with PBS and secondary antibodies diluted in 1% (v/v) goat
serum, 0.2% (v/v) Triton X-100 in PBS were added over night at 4 °C. OSC were washed
three times with PBS and mounted on glass slides.
Primary and secondary antibodies used are described in chapter 5.6.1
5.14 Image analysis
Imaging of immunostained slices was performed using a laser-scanning confocal microscope
(SP2 or SP5, Leica, Heerbrugg, Switzerland). For confocal live imaging studies, OSC
cultured on small confett i-membranes were placed upside down on
µ-slides (Vitaris AG, Baar, Switzerland). Time-lapse imaging was performed using a SP5
laser-scanning confocal microscope (Leica, Heerbrugg, Switzerland) equipped with a
temperature controller and a CO2-box at 37 °C and 5% CO2. A wide-field fluorescence
microscope (IX71, Olympus, Volketswil, Switzerland) served for non-confocal live imaging.
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5.15 PMO crosslinking
5.15.1 Peptides, PMO and crosslinker
The following PMO were obtained from GeneTool (Philomath, OR, USA): anti-GFP-
Lissamine: GAT CCG AAG CCT GCT TTT TTG TAC; anti-CFP-Lissamine: ACA GCT CCT
CGC CTT GCT CAC CAT; anti-msPer2-Lissamine: GGA GAA GTC CAC GTA TCC ATT
CATG. PMO were solubilized in sodium phosphate buffer (50 mM, pH 7.2) containing 20%
(v/v) CH3CN to a final concentration of 1 nmol/µl. Peptides were synthesized by GeneScript
(Piscataway, NJ, USA): pTAT: CYGRKKRRYRRR; pR9F2C: RRRRRRRRRFFC. The
peptides were reconstituted in sodium phosphate buffer (50 mM, pH 6.5, 5 mM EDTA) to a
final concentration of 2.5 nmol/µl. The Sulfo-LC-SPDP and Sulfo-KMUS crosslinker were
obtained from Perbio Science (Lausanne, Switzerland). The crosslinker were dissolved in
dimethyl sulfoxide (DMSO) to a final concentration of 0.1 mg/ml.
5.15.2 Crosslinking PMO and peptide
PMO and crosslinker were mixed at a 1:2 PMO:crosslinker molar ratio and incubated at room
temperature for 30 min in the dark on a rotating wheel. The product was precipitated with a
30- fo ld  excess of  co ld  acetone ( -20 °C)  and cent r i fuged at
4000 rpm for 10 min at 4 °C. Supernatant was discarded and pellet was air dried for 20 min,
before resuspended in 1 ml sodium phosphate buffer (50 mM, pH 6.5, 5 mM EDTA)
containing 20% (v/v) CH3CN. Peptide and PMO were mixed at a 2:1 peptide:PMO molar ratio
and incubated over night at room temperature in the dark on a rotating wheel. The conjugate
was purified using D-Salt Plyacrylamide 1800 Desalting Gel column (Perbio Science,
Lausanne, Switzerland).
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7 Abbreviations
AraC Cytosine arabinoside
BCR B cell receptor
BrdU Bromodesoxyuridin
CDR Complementarity-determining region
CIS Clinically isolated symptom
CNPase 2', 3'-cyclic nucleotide 3'-phosphodiesterase
CNS Central nervous system
CSF Cerebrospinal fluid
D segment Diversifiying segment
DNA Deoxyribonucleic acid
E.coli Escherichia coli
EAE Experimental autoimmune encephalomyelitis
EBV Ebstain Barr virus
ELISA Enzyme linked immunosorbent assay
FACS Fluorescence activated cell sorting
Fc Fragment crystallizable
FDC Follicular dendritic cell
GFAP Glial fibrillary acidic protein
GFP Green fluorescent protein
GlcNAc N-acetyl-b-D-glucosamine
h Hour
HC Healthy control
HLA Human leukocyte antigen
HSVTK Herpes simplex virus tyrosine kinase
IFN Interferon
Ig Immunoglobulin
IGF Insulin growth factor
IL Interleukin
J segment Joining segment
LPS Lipopolysaccharide
lyso-GM1 Lysoganglioside GM1
MAC Membrane attack complex, formed by the complement proteins
C5b, C6, C7, C8, C9
MBP Myelin basic protein
MHC Major histocompatibility complex
MOG Myelin oligodendrocyte glycoprotein
Abbreviations
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MRI Magnetic resonance imaging
MS Multiple Sclerosis
MS-mAb Monoclonal antibodies derived from MS CSF plasma cells
NAWM Normal appearing white matter
NF Neurofilament
NG2 Chondroitin sulphate proteoglycan NG2; marker for OPC
OCB Oligoclonal Ig band
OIND Other inflammatory neurological diseases
OPC Oligodendrocyte precursor cell
OSC Organotypic slice culture
PCR Polymerase chain reaction
Per2 Period2
PI Propidium iodide
PLP Proteolipid protein
PLP-GFP GFP wxpressed under regulatory sequences of PLP
PMO Phosphorodiamidate morpholino oligo
PP-MS Primary progressive multiple sclerosis
RAG Recombination activating genes
RR-MS Relapsing-remitting multiple sclerosis
RT Reverse transcription
SC-PCR Single cell reverse transcriptase PCR
SP-MS Secondary progressive multiple sclerosis
TCR T cell receptor
TGF Transforming growth factor
TH cell CD4+ T helper cell
TNF-a Tumor necrosis factor -a
V segment Variable segment
Curriculum Vitae
-85-
8 Curriculum Vitae
Melanie D. Harrer
Date of birth: 10th of September 1979
Nationality: Double Citizenship Swiss and Austrian (EU)
Education
Since 10.2004 Thesis Work (PhD) in the group of Prof. Dr. med N. Goebels, Clinical
Neuroimmunology, University Hospital Zurich
02.2006 Introductory course in Laboratory Animal Science (LTK Modul 1)
10.1999 - 04.2004 Master of Science in Biochemistry and Molecular Biology at the
Swiss Federal Institute of Technology (ETH), Zurich, Switzerland
03.2003 – 10.2003 Master thesis in the group of Dr. B. Martoglio, ETH Zurich
11.2002 – 03.2003 Semester work in the group of Dr. B. Martoglio, ETH Zurich
07.2002 – 08.2002 Semester practical course in the group of Dr. R. Kroschewski, ETH
Zurich
03.1999 – 09.1999 Au pair and attendance of language school (First Certificate in English,
Grade A), Guildford, Great Britain
07.1992 - 02.1999 High School and Swiss Federal Maturity, Typus B, Realgymnasium
Rämibühl, Zurich, Switzerland
Curriculum Vitae
-86-
Publications
Kuenzle S, von Büdingen HC, Meier M, Harrer MD, Urich E, Becher B and Goebels N.
Pathogen specificity and autoimmunity are distinct features of antigen-driven immune
responses in neuroborreliosis. INFECTION AND IMMUNITY. 2007, Vol. 75, No. 8: p.
3842–3847
von Büdingen HC*, Harrer MD*, Kuenzle S*, Meier M and Goebels N. *HCVB, MDH and SK
contributed equally. Clonally expanded plasma cells in the CSF of MS patients produce CNS
spec i f i c  immunog lobu l i ns .  Eu r .  J .  Immuno l .  2008 .  Vo l .  38 :
p. 2014–202
Harrer MD, von Büdingen HC, Stoppini L, Alliod C, Pouly S, Fischer K and Goebels N.
Remyelination after antibody-mediated demyelination in an ex vivo model for immune
mediated CNS damage. Submitted
Sobottka B, Harrer MD, Ziegler U, Becher B, Hünig T, Goebels N. Confocal live imaging
reveals direct transsection of myelinated axons by antigen-specific CD8+ T cells. Submitted.
Financial support
-87-
9 Financial support
This work was funded by grants provided to N. Goebels by the National Center for
Competence in Research (NCCR) Neural Plasticity and Repair, the Neuroscience Center
Zurich, Merck-Serono SA Geneva, the Swiss Multiple Sclerosis Society, the Swiss National
Science Foundation, and the University of Zurich. Especially, my position was funded by the
3R Research Foundation Switzerland, to which I would like to express my special gratitude.
Acknowledgments
-88-
10  Acknowledgments
First of all, I would like to thank Norbert Goebels, for the opportunity to do my PhD studies in
the field of neuroimmunology. I appreciated the freedom of action and independency during
my PhD thesis. I thank my supervisors Adriano Aguzzi, Burkhard Becher and Rolf
Zinkernagel for supporting my work with helpful discussions. Luc Stoppini, Beat Gähwiler and
Lotty Rietschin, Luis Craveiro and Jeppe Pederson Falsig for help with slice cultures Thanks
go to. Karl Frei for providing me with human brain tissue. I would like to thank M. Höchli and
Urs Ziegler (Center for Microscopy and Image Analysis, University of Zurich) for help with
confocal and live microscopy
I would like to thank Christian von Büdingen. It was a great time to work with and for you and
to discuss with you the ongoing projects. I thank all the current and former lab members for
their help, exciting discussions and relaxing chats – especially Katja Fischer, not only for her
never ending story with antibody production but in particular for all the great time we had
together. I also thank all the members of the Becher-, Fontana- and Frei-Groups for their
discussions and help not only during the progress reports.
Special thanks go to Marco Kuster, thank you for your continuous support and cheering me
up during the hard phases of my PhD and last but not least to my mother, who always
supported my studies and encouraged me to go on and to give my best.

